University of Groningen

Interventional Bronchoscopy

Criner, Gerard J; Eberhardt, Ralf; Fernandez-Bussy, Sebastian; Gompelmann, Daniela; Maldonado, Fabien; Patel, Neal; Shah, Pallav L; Slebos, Dirk-Jan; Valipour, Arschang; Wahidi, Momen M

Published in:
American Journal of Respiratory and Critical Care Medicine

DOI:
[10.1164/rccm.201907-1292SO](https://doi.org/10.1164/rccm.201907-1292SO)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Final author's version (accepted by publisher, after peer review)

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Criner, G. J., Eberhardt, R., Fernandez-Bussy, S., Gompelmann, D., Maldonado, F., Patel, N., Shah, P. L., Slebos, D-J., Valipour, A., Wahidi, M. M., Weir, M., & Herth, F. F. J. (2020). Interventional Bronchoscopy: State-of-the-Art Review. *American Journal of Respiratory and Critical Care Medicine*, 202(1), 29-50. <https://doi.org/10.1164/rccm.201907-1292SO>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Interventional Bronchoscopy: State-of-the-Art Review

Gerard J. Criner, M.D.,¹⁺ Ralf Eberhardt, M.D.,² Sebastian Fernandez-Bussy, M.D.,³ Daniela Gompelmann, M.D.,² Fabien Maldonado, M.D.,⁴ Neal Patel, M.D.,³ Pallav L. Shah, M.D.,⁵ Dirk-Jan Slebos, M.D.,⁶ Arschang Valipour, M.D.,⁷ Momen M. Wahidi, M.D.,⁸ Mark Weir, M.D.,¹ and Felix F.J. Herth, M.D.²

¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA; ² Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany; ³ Division of Pulmonary Medicine, Mayo Clinic, Jacksonville, Florida. USA.; ⁴ Departments of Medicine and Thoracic Surgery, Vanderbilt University, Nashville, TN; ⁵Respiratory Medicine at the Royal Brompton Hospital and National Heart & Lung Institute, Imperial College, London, UK; ⁶ Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, The Netherlands; ⁷ Department of Respiratory and Critical Care Medicine, Krankenhaus Nord, Vienna, Austria; ⁸ Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Duke University School of Medicine

+ Associate Editor, AJRCCM (participation complies with American Thoracic Society requirements for recusal from review and decisions for authored works).

Reprint request and correspondence:

Gerard J. Criner, M.D.

Department of Thoracic Medicine and Surgery

Lewis Katz School of Medicine at Temple University

745 Parkinson Pavilion

3401 North Broad Street

Philadelphia, Pa. 19140

Office: 215-707-8113

Fax: 215-707-6867

Email: gerard.criner@tuhs.temple.edu

Key words: emphysema, lung cancer, chronic bronchitis, bronchoscopy

Abstract word count: 231 words

Body word count: 7,540

Table count: 2

Figure count: 10

Abstract

For over 150 years, bronchoscopy, especially flexible bronchoscopy, has been a mainstay for airway inspection, the diagnosis of airway lesions, therapeutic aspiration of airway secretions and transbronchial biopsy to diagnose parenchymal lung disorders. Its utility for the diagnosis of peripheral pulmonary nodules and therapeutic treatments besides aspiration of airway secretions, however, has been limited. Challenges to the wider use of flexible bronchoscopy have included difficulty in navigating to the lung periphery, the avoidance of vasculature structures when performing diagnostic biopsies and the ability to biopsy a lesion under direct visualization. The last 10-15 years has seen major advances in thoracic imaging, navigational platforms to direct the bronchoscopist to lung lesions and the ability to visualize lesions during biopsy. Moreover, multiple new techniques have either become recently available, or are currently being investigated to treat a broad range of airway and lung parenchymal diseases such as asthma, emphysema, chronic bronchitis or to alleviate recurrent exacerbations. New bronchoscopic therapies are also being investigated to not only diagnose, but possibly treat malignant peripheral lung nodules. As a result, flexible bronchoscopy is now able to provide a new and expanding armamentarium of diagnostic and therapeutic tools to treat patients with a variety of lung diseases. This state-of-the-art review succinctly reviews these techniques and provides clinicians an organized approach to their role in the diagnosis and treatment of a range of lung diseases.

Introduction

For over 150 years, bronchoscopy has been instrumental in the inspection and diagnosis of airway and parenchymal lung diseases.⁽¹⁾ Recently, the capabilities of bronchoscopy to diagnose and treat a variety of lung diseases has expanded. Bronchoscope designs with enhanced optics, greater resolution, flexibility and smaller size but with functional working channels are key to these advances.

High-resolution chest CT (HRCT) imaging provides enhanced structural detail of lung lesions and coupled with navigational technology provides endoscopic roadmaps to small distal lesions. HRCT imaging can construct pulmonary vasculature maps and provide virtual avascular paths to lesions that lack a leading bronchus. Incorporation of real-time imaging during bronchoscopy can provide precision location of difficult to reach targets.

Simultaneously, advances in endobronchial ultrasound coupled with instruments that can aspirate, biopsy, cut, brush, freeze, ablate, and vaporize tissue provides an array of modalities to diagnose and treat many lung diseases. (Table 1)

Bronchoscopic interventions in selected patients with asthma and emphysema provides new treatment options. Current research focused on treating chronic bronchitis, fixed airflow obstruction and lung cancer offer the possibility of less invasive, but effective therapies. (Table 2)

Herein, we review recent advances in the diagnostic and therapeutic applications of bronchoscopy.

Interventional bronchoscopy for lung cancer diagnosis and treatment

Modalities that enhance imaging and provide bronchoscopic navigation to lung lesions

Several imaging modalities can improve access to peripheral lesions. Some modalities provide real-time imaging during navigation (convex endobronchial ultrasound (EBUS), radial endobronchial ultrasound (rEBUS), fluoroscopy and CT imaging modalities); others use planning HRCTs to create navigational paths. A patient's condition during planning HRCT is different compared to the procedure; spontaneous respiration vs. intubation plus mechanical ventilation, anesthesia and paralysis, and higher inspired O₂, respectively. The latter results in atelectasis and creates CT-to-body divergence. CT-to-body divergence describes differences in targeted lesion locations identified pre-procedurally by HRCT and its location during bronchoscopy. CT-to-body divergence is more important than nodule size in adversely affecting diagnostic yield and a crucial barrier to ablation.(2) The following modalities have been developed to address this obstacle, however, it none of the technologies have been directly compared for diagnostic yields or cost-effectiveness.

Imaging techniques

Radial EBUS (rEBUS)

Launched in 1999, rEBUS (Olympus Cooperation, Tokyo, Japan) uses a flexible catheter and rotating ultrasound transducer to produce 360° ultrasound images, it was first used to guide transbronchial lung biopsy (TBLB) (3). During bronchoscopy, the 20-MHz mechanical probe is inserted through a guide sheath into the lung periphery. Figure 1 shows a typical ultrasonographic image.

rEBUS is the most commonly used real-time technique to confirm a lesion during diagnosis and probe placement during therapeutic interventions. However, discordance has been reported for diagnostic yields amongst studies.

Steinfort (4) evaluated > 1,400 patients with rEBUS guided transbronchial biopsy and showed a specificity of 1.00 and sensitivity of 0.73 for lung cancer diagnoses. Variations in diagnostic sensitivities were attributed to the prevalence of malignancy, lesion size, probe position and use of fluoroscopy. In a multicentered controlled trial, the diagnostic yield of thin bronchoscope (TB) plus rEBUS was compared with standard bronchoscopy and fluoroscopy (SB-F); average lesion size was 31.2 ± 10.8 mm.(5) Diagnostic yield was higher with TB-rEBUS compared to SB-F (49% vs 37) but was not statistically significant.

Several reasons may explain differences in diagnostic yield bedside lesion characteristics. rEBUS probes are not steerable; navigation support might be useful especially in lesions < 2 cm. Eberhardt (6) reported that EBUS with electromagnetic navigational bronchoscopy (ENB) beneficially combines real-time imaging with steerability. Diagnostic yields of the combined procedure are greater than rEBUS or ENB alone. Others have confirmed this finding. (7). An opportunity exists to improve rEBUS imaging, especially semisolid lesions, to enhance diagnostic accuracy.(8)

Navigational techniques

ENB (electromagnetic navigational bronchoscopy)

ENB systems (Medtronic, Inc., Minneapolis, USA) assist placing biopsy tools into lesions. It uses low-frequency electromagnetic waves emitted from an electromagnetic board placed under the patient. A sensor probe is mounted on a cable tip and a flexible catheter provides biopsy tool access (9).

Meta-analyses report diagnostic accuracies of 70-75%.(10-12). Lesion location, nodule size, an existing bronchus sign, procedural error and biopsy technique all affect diagnostic yield. A prospective multicenter study (NAVIGATE) evaluated ENB using the superDimension navigation system (Medtronic, Minneapolis, MN) in patients with median nodule size 20 mm.(13) In 1,157 patients that underwent ENB, 94% had navigation completed; diagnostic yield was 73%. The system recently added tomosynthesis (serial x-rays images during c-arm rotation) to improve real-time fluoroscopic evaluation and address CT-to body divergence.

The SPiN® Thoracic Navigation System (Veran Medical Technologies, Inc., St. Louis, USA) is an ENB platform that uses respiratory gating technology to track moving nodules during endoscopic or transthoracic lung nodule biopsy. (14) Biopsy instruments have electromagnetic sensors that guide and track the path to the target and also addresses CT-to-body divergence.

VBN (Virtual bronchoscopic navigation) and Augmented Fluoroscopy

Virtual bronchoscopic images of the bronchial path to a peripheral lesion are generated by software using HRCT data. During bronchoscopy, the virtual navigational image is projected on a display screen and compared to real-time images. Eberhardt (15) reported a 80% diagnostic yield in patients with solitary pulmonary nodules. Diagnostic yield with VBN depended upon lesion size, lobar location and bronchus sign presence.

Visual guidance to targeted lesion is superimposed onto the endoscopic image (LungPoint (Broncus Medical, Mountain View, California, USA). An image-based registration technique aligns virtual images with live bronchoscopic video. Once near the target, the lesion shape is overlaid onto the airway wall to provide biopsy guidance (Figure 2). Lesion shape is overlaid onto live fluoroscopic images (e.g., fused fluoroscopy or augmented fluoroscopy).

Another system uses real-time endobronchial augmented fluoroscopic navigation (BodyVision Medical Ltd., Israel). This system enables lesion tracking during breathing movement and may improve lesion localization and diagnostic yield. (16)

Others report that VBN-guided (Olympus Medical Systems, Tokyo, Japan) rEBUS-transbronchial diagnosis without fluoroscopy has equivalent diagnostic yield to fluoroscopy in nodules with a bronchus sign.(17) Comparative evaluation of these techniques is required.

Transparenchymal Nodule access (TPNA)

rEBUS, VBN, ultrathin scopes and ENB improves diagnostic yield of pulmonary nodules compared to standard bronchoscopy; however, diagnostic yield still depends on lesion size, lesion location and presence of a bronchus sign.

Some nodules lack a bronchus sign and are so distant from a bronchus that bronchoscopic sampling techniques fail. For these situations, Transparenchymal Nodule Access (TPNA) was developed. The Archimedes Virtual Bronchoscopy Navigation System (Broncus Medical, Mountain View, Calif., USA) reconstructs HRCT data into a 3D model to provide virtual guidance of sheath placement through an airway wall and lung parenchyma into a lesion. (18, 19)

A sheath with radiopaque marker bands is used to tunnel through lung parenchyma to the nodule, samples are taken real-time under fused fluoroscopic guidance (Figure 3, Panel A).

Herth (20) presented a dataset at the ERS conference showing that the yield of TPNA depends on lesion size.

The transbronchial access tool (TBAT; CrossCountry™ TBAT, Medtronic, Minneapolis, MN) biopsies peripheral lung nodules using rEBUS or ENB or rEBUS + ENB to diagnose peripheral lung nodules. (Figure 3, Panel B). TBAT with rEBUS and ENB plus cone beam CT may

increase diagnostic yield close to 100%.(21-23) Procedural time and radiation exposure is higher with use of CT. More data is needed to confirm the success of this technique.

Imaging and Navigation

CT Bronchoscopy

Computed tomography (CT)-guided biopsy helps the bronchoscopist biopsy fluoroscopically invisible lesions. Ultrathin bronchoscopy with CT guidance has 79% and 80% diagnostic sensitivities when a bronchus or artery is at the center of the lesion, respectively.(24) Combining VBN with CT-guided biopsy using an ultrathin bronchoscope may be helpful, especially LUL lesions .(25) (24) Others failed to increase diagnostic yield with CT guidance suggesting that technical expertise may be crucial. (26) Lesion location (superior segment of lower lobes), more distal navigation, and a CT bronchus or artery sign affects diagnostic yields. (24) Cone beam CT (CBCT) imaging to diagnose lung lesions is a modification of techniques used in digital angiography.(27-29) With this technique, CBCT images are obtained and the target is overlaid on fluoroscopic images. Real-time multiplanar confirmation of lesion location in relationship to biopsy tools addresses CT-to-body divergence. A drawback is radiation bursts used to procure images during CBCT “spins. One report using CBCT with real-time ENB with or without rEBUS reported navigational and diagnostic yields of 91% and 70%, respectively.(28) In malignant cases, diagnostic yield was 82% for lesions within 25 ± 18 mm of the pleura. (28) A study using CBCT with augmented fluoroscopy (Philips Allura Xper FD20 system with Oncosuite); PhilipsHealth, UK) plus ENB reported a diagnostic yield of 83.7%; there was no relationship between diagnostic yield and lesion size, location, fluoroscopic visibility or bronchus sign. (30) CBCT with ENB and hook-wire localization enhances diagnosis and resection of lung lesions during the same session. (27) Further investigation should compare CBCT diagnostic yield vs. less costly modalities with lower radiation exposures.

Adjunctive bronchoscopic local imaging techniques

Lung cancer screening has precipitated a shift from central to more peripheral nodules for lung cancer evaluation. This has prompted development of new techniques based on sound optical, biochemical and physiological principles to provide greater *in vivo* guidance while biopsying small lung lesions. The clinical value of these techniques are currently unknown but have potential to help diagnose peripheral lung cancers.

Optical coherence tomography (OCT)

OCT uses near infrared light to create high-resolution images at a 'histology' level with 10-15 μ m resolution and 2-3mm depth. (31) It can identify and quantify changes in airway walls (32, 33), histologically examine lung parenchyma(34-36), and examine nodules and pulmonary vasculature. Images are captured using a 1mm probe via the bronchoscope. OCT's clinical applications include identifying bronchial lesions, (37-39) airway remodeling,(40-43) subtyping interstitial lung diseases (ILD)(44),and assessing vascular lesions due to pulmonary arterial hypertension (45, 46) or thromboembolic disease.(47)

OCT has been used with other modalities to enhance diagnostic yield. Autofluorescence bronchoscopy-guided OCT imaging provides *in vivo* imaging of preneoplastic bronchial lesions to study their natural history and the effects of chemopreventive intervention. In high-risk heavy smokers, Lam reported that dysplasia and carcinoma *in situ* (CIS) can be distinguished from lower-grade lesions.(37) Polarization-sensitive OCT (PS-OCT) is another OCT imaging modality that is endoscope- and/or needle-compatible. It provides large volumetric views of lung tissue microstructure at high resolution (e.g., 10 μ m) while simultaneously measuring birefringence of organized tissues like collagen or airway smooth muscle. In 64 lung nodule samples, PS-OCT accurately classified tumor regions with higher (>20%) from lower fibrosis thus yielding higher tumor content with PS-OCT directed biopsy.(48)

Confocal laser endomicroscopy (CLE)

CLE uses low power laser bundles to create real-time microscopic images at a “cellular” level. CLE has a resolution up to 3.5µm, with a 240µm maximum depth and 600µm field of view.(47) Contrast can enhance visualization of different cellular/tissue components. Images are captured using a probe-based CLE via bronchoscope or 19-gauge needle. It may help detect lung cancer, (49-51)ILD(52, 53), lung allograft rejection (54)and mediastinal lymph node pathology.(55)

Image enhancement

Autofluorescence bronchoscopy (AFB) utilizes green and red spectrum light to detect mucosal alterations. Normal mucosa presents green color, while precancerous and cancerous lesions absorb the green spectrum and turn magenta. Narrow band imaging (NBI) removes all wavelengths except two that are absorbed by hemoglobin thereby creating contrast between the vasculature (Cyan) and surrounding mucosa (Brown). AFB(56)and NBI (57-60)are superior to white light bronchoscopy in detecting dysplasia, CIS or invasive carcinoma.(61) Image enhancement has struggled for a role in bronchoscopy because no well-defined population exists for general use,(62) poor standardization of pathological dysplastic criteria and weak evidence for treatment of CIS.(63) It may be useful in patients with abnormal sputum cytology or previous dysplasia to delineate tumor margins.(64)

Thin convex probe endobronchial ultrasound (Thin-EBUS)

Convex probe endobronchial ultrasound is designed for mediastinal and hilar lymph node staging and has limited size and flexibility to direct biopsy of lung lesions except those centrally located. Development of a Thin-EBUS scope that has smaller size and greater flexibility may improve smaller airway access.(65) In ex-vivo human lungs, it provides superior access to

segmental and subsegmental bronchi.(66) Thin-EBUS could provide better access to interlobar lymph nodes and peripheral lung lesions.

Technological changes in the Bronchoscope

Ultrathin bronchoscopy

The small size of the peripheral airways limits the ability of conventional bronchoscopes to navigate to peripheral lesions. The working channel of conventional pediatric bronchoscopes limits the size of tools needed to diagnose peripheral nodules. (67) Development of ultrathin bronchoscopes (~2.8 -3.5 mm outer diameter) allows for greater maneuverability to traverse small airways. Although no strict definition of ultrathin exists; most have outer dimensions ≤ 3.2 mm. A retrospective analysis of 209 malignant lesions biopsied with an ultrathin bronchoscope reported diagnostic yields of 63% in lesions ≤ 2 cm. (68)A metanalysis of ultrathin bronchoscopy reported an overall diagnostic yield of 70% when combined with other modalities (e.g., VBN, rEBUS and fluoroscopy). (69) A concern is that working channel size limits the size of collected specimens. A multicentered trial reported that ultrathin bronchoscopy was superior to thin bronchoscopy to diagnose peripheral lung nodules ≤ 30 mm. (68). The ultrathin bronchoscope reached more distal bronchi (median fifth vs. fourth generation bronchi). Diagnosis of benign disorders was lower than malignant lesions despite using the ultrathin bronchoscope.(70) The type of image guidance (fluoroscopy vs VBN vs CT) used with the ultrathin bronchoscope and sampled lobe impacts diagnostic yields.(24, 25, 71)

Robotic bronchoscopy

Robotic-assisted bronchoscope systems can navigate to small peripheral airways under continuous visualization while maintaining a static curved position. This advantage keeps biopsy tools and even ablation devices locked on the targeted lesion despite flexed articulation. (72-74)

Initial experience has been reported in 15 patients.(73) Biopsy samples were taken from 93% of subjects with lesions 2.6 mm in diameter; closest edge was 0.6 mm from the pleura. Cancer was confirmed in 60% of lesions; time to biopsy was 45 minutes in the first five cases and 20 minutes in the last nine. Another robotic device (Ion Endoluminal System (www.intuitive.com/ion) received FDA clearance in August 2019. (<https://www.therobotreport.com/ion-lung-biopsy-intuitive-surgical-fda/>) It has Fiber Optic RealShape (FORS) technology with ultra-thin and maneuverable catheters that navigate to the lung peripheral with maintenance of catheter stability. Fielding studied 29 subjects with mean lesion size of 12.2 ± 4.2 mm; 41.4% had absent CT bronchus sign. In 96.6% of cases, target was reached and samples were obtained.(75) An overall diagnostic yield of 79.3% was reported with 88% yield for malignancy.

Malignant Solitary Pulmonary Nodule: Therapeutic Approaches

Solitary pulmonary nodule

Guidelines recommend surgical resection of early stage non-small cell lung cancer (NSCLC) (76),but many patients are unsuitable (77). The only non-surgical non-pharmacological option is stereotaxic body radiation therapy (SBRT), which is highly effective but not without complications.(78) The need exists for other non-pharmacological options that are similarly effective, but with less complications.

Advances in navigational bronchoscopy enable accessing a lung tumor and treating it. Various bronchoscopic ablation technologies might be possible: radiofrequency ablation (RFA), microwave ablation (MWA), photodynamic therapy (PDT), brachytherapy, cryoablation, vapor thermal ablation or direct therapeutic injection. Most technologies are still in preclinical stages or undergoing small feasibility trials.

Radiofrequency Ablation (RFA)

RFA uses high frequency alternating current to deliver thermal injury with an electrode inserted into the tumor. RFA generates a tissue destruction zone around the electrode tip; treatment zone and tumor death may be affected by surrounding tissue. Damage to aerated lung surrounding tumor is minimized by air's insulating effect. (79, 80) Koizumi (81) reported a local control rate of 83 % using endoscopic RFA; median progression-free survival was 35 months and overall 5-year survival was 61.5%.

Microwave Ablation (MWA)

Microwave ablation is a heat-based therapy that generates an elliptical-shaped electromagnetic field with microwave frequency ranges between 300 MHz to 300 GHz via a probe inserted into the lesion. Like RFA, microwave ablation induces coagulation necrosis by heating target tissue to temperatures > 60°Celsius. An endoscopically directed flexible gas-cooled microwave antenna has been tested in a porcine model (82). Clinical trials with endoscopically delivered MWA are ongoing. (ClinicalTrials.gov Identifiers: NCT03569111; NCT04005157 and NCT03769129).

Cryoablation

Cryoablation causes cell death using alternating freeze and thaw cycles. The exact lethal temperature threshold is unclear; some experiments suggest -20°C as a minimum threshold. Yamauchi reported mean local tumor progression-free interval was 69 months and median survival was 62 months using percutaneous cryoablation in 22 inoperable NSCLC patients (83) Zheng (84) recently reported animal data using a flexible probe; human data is unavailable.

Bronchial Thermal Vapor Ablation (BTVA)

BTVA has been used in bronchoscopic lung volume reduction and may have potential to treat focal cancers. An advantage of water vapor is rapid energy delivery. A porcine model demonstrated that uniform necrosis can be bronchoscopically delivered to a focal lung region (85). A first-in-human trial has begun. (ClinicalTrials.gov Identifier: NCT03198468)

Brachytherapy (HDRT)

HDRT is used to palliate malignant central airway obstructions. Experience for peripheral brachytherapy is limited; only small case series are published (86, 87). Most have used 5 Gy administered 3 times per week. The requirements for repeated applications and placement of a guide sheath are limitations.

Photodynamic Therapy (PDT)

PDT has been used for malignant central airway obstructions and carcinomas-in-situ. After administration of a photosensitizing agent with selective uptake by tumor cells, the photosensitizer is activated endoscopically by a specific laser light. The photosensitizer produces highly reactive oxygen species that cause cell death. Chen (88) treated 3 patients with local control at 1-year. A newly developed parallel-type ultrasmall composite optical fiberscope (Laser-eYe Ultrathin fiberscope [LYU]) couples simultaneous imaging and phototherapy and was effective in preclinical lung cancer models.(89) This new laser device has potential to treat peripheral lung cancers.

Central airway obstruction (CAO)

CAO is symptomatic obstruction of the trachea, mainstem bronchi, bronchus intermedius or lobar bronchi.(90, 91) Tracheal obstruction causes exertional symptoms when tracheal diameter

is 8mm or ~ 30% cross-sectional area, rest symptoms develop < 5mm or <20% cross-sectional area. (92-94)

CAO can be divided into malignant or non-malignant causes. Malignant disease is usually related to locally advanced thoracic malignancies. At presentation approximately 10% of lung cancers have evidence of CAO.(95) Tracheal invasion constitutes a T4 malignancy in the 8th TNM classification,(96) tracheal invasion without metastasis constitutes stage 3A disease with a median survival of 29.3 months, nearly double compared to prior years.(97) Primary tracheal tumors are rare; in adults these are mostly malignant and due to squamous cell carcinoma, adenoid cystic carcinoma or carcinoid.(98) Primary tracheal tumors should be treated with resection for most patients with benign lesions, tumors of intermediate aggressiveness, and localized malignant tumors.(99)

Non-malignant disease includes post-intubation, (100, 101)post-tracheostomy,(93) infection related;(102) transplant airway disease (102)and autoimmune conditions.

CT imaging is essential to evaluate CAO, it provides insight into etiology, extent, morphology and vascular involvement. (103-106) 3D reconstructions with vascular and mediastinal anatomy assists with case planning and stent preparation.

Flexible bronchoscopy evaluates morphology and extent of CAO and can provide diagnostic specimens. (107)Manipulation of CAO with a flexible can be dangerous; even minimal manipulation can cause edema or hemorrhage that precipitates airway compromise.

Therapeutic instruments (laser, APC, stent deployment) can be used with a flexible bronchoscope.(108) Endobronchial ultrasound assesses invasion depth and vascular structures during therapeutic bronchoscopy. (109)

Rigid bronchoscopy is the gold standard for CAO management .(90, 110) It allows airway manipulation with the ability to ventilate, suction and tamponade bleeding while debulking tumor.(107) Its' large working channel allows removal of large tumors and deployment of silicone stents, but can also cause airway damage. A flexible bronchoscope can be inserted via the rigid bronchoscope to enhance maneuverability.

After appropriate patient selection(111, 112) therapeutic bronchoscopy for CAO can be performed with acceptable complications and mortality. (113, 114) Therapeutic bronchoscopy improves quality of life, (114-116), lung function(117) weans patients from ventilation (118), stabilizes patients before definitive therapy, (119) and improves survival similar to comparable cancer stage patients without CAO.(120, 121)

Central airway obstruction (CAO): Treatment

Therapeutic destruction

Therapy for malignant CAO includes mechanical debridement with forceps, cutting tools or mass coring with a rigid bronchoscope. (107) Thermal therapies with laser, APC and electrocautery can provide immediate relief. Depending on the laser and its settings, it can be a cutting tool, or can coagulate and vaporize the tumor. There is a low rate of laser related complications; but hemorrhage, airway fire, and fistula have been reported.(122-125) APC is not ideal for large tumors but helps with mechanical debulking by coagulating the tumor and controlling bleeding. (126) Electrocautery can be used but requires tissue debulking.(127) Thermal therapies require reduced oxygen environments which limits use in hypoxemic patients.

Photodynamic therapy (PDT)

Photodynamic therapy (PDT) is indicated for non-operable malignant CAO. (128) The effect is delayed and requires repeat bronchoscopy for airway clearance. Adverse reactions include photosensitive skin rash and hemoptysis.(129)

Cryotherapy

Cryotherapy can be used as a spray (130) or a probe (131) for malignant and non-malignant CAO. The cryoprobe requires removal from the airway between biopsies; serious hemorrhage has been reported.

Microdebrider

A microdebrider is a hollow suction tube with an internal rotary blade; the tissue is macerated by the blade and simultaneously removed by suction. This allows field visualization and rapid debridement without perforation. (132, 133)

Airway dilation

Airway dilation uses high pressure catheter balloons, bougie devices or a rigid bronchoscope. (134) Dilation is combined with other therapies; radial incisions for focal stenosis to prevent mucosal tear(135), debridement of tissue, and stent placement.(136-138) Sustained airway patency after balloon dilation is variable(139, 140); the procedure usually needs repeating, surgery, or stenting for recalcitrant disease.(141) Attempts to sustain benefit with drug eluting balloons has been reported.(142)

Chemo injection

Direct injection of chemotherapeutic agents into CAO has been reported to be feasible. (143-145)

Stents

When selecting a stent to manage CAO, one must consider the disease process, radial force required, duration of use and insertion technique. The ideal stent should be: (1) easy to insert and remove, yet not migrate; (2) of sufficient strength to support the airway but flexible enough to promote secretion clearance; (3) biologically inert to minimize granulation tissue; and (4) available in multiple sizes. (90)

Silicone stents developed (146) are inserted via a rigid bronchoscope, they are inexpensive, easy to modify, and remove. The major issues are mucostasis (147) and migration. Silicone stents have reduced granulation tissue reaction, (148) the silicone Y stent is ideal for lesions at the carina or dynamic collapse of the distal trachea and mainstem bronchi. (91)

Self-expandable metal stents (SEMS) are the most commonly used stents. SEMS conform to the airway and have favorable internal to external diameters that aids mucus clearance.

Indications include recurrent stenosis; malignant airway obstruction (9, 149-151) and transplant airway stenosis. (152-154) They are used in expiratory central airway collapse to predict response to tracheoplasty. (155)

Balloon-expandable metal stents are malleable, they can be bent and perforated to aerate collateral bronchi. Currently, their limited diameters make them most useful in lobar airways. (156, 157)

Benign CAO patients' survive longer than malignant patients and thus experience more complications. (150) Attempts to circumvent these issues have led to stents made with biodegradable polymers.(158) Use of these stents is limited to reports in pediatric patients and transplant airway disease. (159-163)A pilot study in adults with transplant airway complications reported biodegradable stents to be effective but required repeated procedures(161) (158)

The tracheobronchial tree is well suited to 3D printing using multidetector CT data. 3D models have been used for procedure planning, stent design and assessment of flow limitation.(164-169)

Agents may be applied to stents that could retard bacterial colonization, granulation tissue formation or malignant growth. (29)

Mediastinal Lymph Node Staging

Real-time endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for lung cancer staging was introduced in 2003. (170) Since then, EBUS-TBNA has become essential for minimally invasive sampling of mediastinal lymph nodes for non-small cell lung cancer (NSCLC).(171) (172)

EBUS-TBNA is the initial modality for lung cancer staging for multiple reasons. The first is less than ideal assessment by staging modalities such as positron emission tomography-computed tomography (PET-CT). Next is its excellent safety profile. Complication rates from multiple databases reports EBUS associated complication rates at ~ 1%. Most complications are minor (cough, bleeding at puncture site) but more serious complications (pneumothorax, mediastinitis, pericarditis and death) have been reported.(173) The diagnostic accuracy of EBUS-TBNA is similar to mediastinoscopy.(171-174) Compared to mediastinoscopy alone, when EBUS-TBNA and mediastinoscopy are used in conjunction, the sensitivity for detection of mediastinal

metastasis improves from 79% to 94%.⁽¹⁷⁵⁾ Follow-up data revealed similar 5yr survivals between endoscopic and surgical staged groups. ⁽¹⁷⁶⁾

Standard practices for EBUS-TBNA staging involves evaluation and sampling of N3 nodal stations, followed by N2 and N1 stations. Sampling all lymph nodes > 5mm in short axis is optimal to maximize procedure sensitivity.⁽¹⁷⁷⁾ Stations traditionally accessible by EBUS-TBNA include 2R/2L, 4R/4L, 7, 10R/10L and 11R/11L. Stations 5 and 6 are inaccessible by EBUS-TBNA, unless a transvascular approach is employed. In place of bronchoscopic ultrasound, transesophageal and gastric use of the EBUS scope (EUS-B), can be performed. EUS-B allows more complete staging of lung cancer patients including stations 8 and 9, and alternative access to stations 2L and 4L. ⁽¹⁷⁸⁾ EBUS can evaluate airway tumor infiltration better than CT imaging.⁽¹⁷⁹⁾

Technical aspects of EBUS-TBNA may maximize procedural yield. Aspiration needles come in 19g, 21g, 22g, and 25g sizes. Trials comparing 21g to 22g, as well as use of a 19g needle show improved sample volume with larger needle size, but larger needle size has not been shown to correlate with diagnostic yield.^(180, 181) Larger needles may be considered if lymphoma or sarcoidosis is suspected. Use of mini-forceps via EBUS may increase sample volume.⁽¹⁸²⁾

In the NSCLC era of tumor molecular analysis, sample adequacy is important in lung cancer staging. During node sampling, diagnostic yield plateaus after three passes.⁽¹⁸³⁾ Rapid on-site evaluation (ROSE) ensures adequate sampling and reduces needle passes.⁽¹⁸⁴⁾ EBUS-TBNA sampling is adequate for generation molecular analysis including ALK, EGFR mutations and PDL1 expression.^(185, 186)

Ultrasound characteristics of lymph nodes provide insight into underlying pathology.

Independent predictors of metastasis included rounded shape, distinct margins, heterogeneous

echogenicity, and coagulation necrosis.(187) An aggregate scoring system that uses the presence of matting, non-hilar vascular pattern perfusion, absence of central hilar structure, and rounded shape had a sensitivity of 93%, specificity of 55%, positive predictive value of 73%, and negative predictive value of 82% to predict malignancy if at least two factors were present.(188)

Elastography

Elastography has been used in breast, thyroid, and hepatic diseases to measure elastic properties. It has also been used to evaluate mediastinal lymph nodes. The color map used with elastography includes red, yellow, green and blue corresponding respectively from least to most stiff. Elastogram colormetric patterns comprise three groups: Type 1 homogeneous green (predominantly green with yellow and red areas), Type 2 mixed (predominantly green with focal blue areas), or Type 3 homogeneous blue (predominantly blue). (Figure 4)

Current data suggests that EBUS-Elastography is safe and may provide predictive information regarding malignant lymph node infiltration. Whether EBUS-Elastography precludes TBNA of lymph nodes is uncertain. A study using similar classification types found a sensitivity of 87%, specificity of 68%, positive predictive value of 80%, and negative predictive value of 77% when type 1 was considered benign, and type 3 malignant.(189)

Obstructive lung diseases: Interventional bronchoscopic treatment

Asthma

Despite a multiple inhaled therapies, patients with asthma may remain symptomatic and require chronic oral steroids or expensive biologics. Consequently, a need exists for other therapeutic options.

Bronchial Thermoplasty

Bronchial thermoplasty is an effective bronchoscopic treatment for asthma. Smooth muscle hypertrophy is key in severe asthma and its reduction may alleviate symptoms and down-regulate airway inflammation. Bronchial thermoplasty is a catheter-based therapy that utilizes radio-frequency energy to heat the airways. A thermocouple within the catheter detects temperature and algorithms within the generator allows smooth muscle temperature to reach 65°C to induce permanent smooth muscle ablation. (190) The mechanism of action was demonstrated by short- and long-term canine studies and has been confirmed in humans. (191-195)

Clinical Evidence

Two cohort and two randomized controlled trials have reported that bronchial thermoplasty is safe and effective in patients with mild to severe asthma. A study in mild to moderate asthma patients demonstrated reductions in symptoms and reduced bronchial hyper-responsiveness. (196) A subsequent study in moderately severe patients (AIR Trial) confirmed improvements in quality of life and symptom scores, but no change in pulmonary function. (197) An uncontrolled study in 30 patients with severe disease (RISA Study) reported benefits in asthma symptom scores and quality of life. (198) A 50% reduction in steroid dose has been reported following bronchial thermoplasty in steroid dependent patients. (198).

A sham-controlled study was performed in symptomatic patients with moderate to severe asthma on high dose inhaled steroids. (199) After bronchial thermoplasty there were significant improvements in asthma quality of life questionnaire measures (AQLQ) and reduced exacerbations, healthcare utilization and days lost from work or education. Reductions in exacerbations and hospitalizations were maintained long term. (200)

Real Life Treatment Experience

The US study (PAS2 Study, Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma) collected registry data and demonstrated similar benefits to AIR2. (201) There was a 44% reduction in severe asthma exacerbations and 55% decrease in emergency room attendance following bronchial thermoplasty.

Future Endoscopic Options

Historical studies suggest a role of the parasympathetic nervous system in hypersensitivity and benefit with denervation. Targeted lung denervation has been studied in COPD but may also have a therapeutic role in severe persistent asthma.

Bronchoscopic Treatment of Emphysema

Multiple interventional possibilities, both surgical and bronchoscopic, exist for patients with advanced emphysema based on clinical, physiological, and radiological assessment. Figure 5 provides an overview of treatments based on clinical assessment.

Endoscopic Valve Placement

In patients with severe emphysema, destruction of the lung leads to both a reduction of gas exchange surface and static and dynamic hyperinflation. Therapeutic strategies aim to reduce air-trapping in order to improve respiratory mechanics, physical activity and even symptoms(202, 203).

Endoscopic valve placement via a flexible bronchoscope is a minimally invasive technique that mimics the benefits of lung volume reduction surgery (LVRS). Two types of one-way valves are commercially available: IBV (Spiration, Olympus, Tokyo, Japan) and EBV (Zephyr, Pulmonx, Inc., Neuchatel, Switzerland), they have different shapes but similar function. Both block inspired air

entry into the treated lobe while air and secretions escape during expiration. Although IBV was originally used for bilateral treatment with incomplete occlusion (204, 205), unilateral lobar occlusion of the most diseased lobe is the preferred technique for either valve(206).(Figure 6)

Valve treatment is suggested only in patients without collateral ventilation (CV)(207). Absent or low CV is presumed in cases with complete fissures on computed tomography (CT). However, CV can also be measured endoscopically with the Chartis system (Pulmonx, Inc., Neuchatel, Switzerland)(208). Using these criteria, RCTs show clinically meaningful improvements in pulmonary function testing, 6-MWD and quality of life (QoL). Mean changes in FEV₁ $\geq$ than +20% and an increase of 33m to 79m in 6-MWD were reported. Although interindividual variability in response is high, 60% of treated patients achieve minimal clinically important difference (MCID) in outcomes(209-211).

In approximately 20-30% of treated patients a postinterventional pneumothorax is expected; it most frequently occurs in the first three days and can be life-threatening. Pneumothorax usually requires chest tube placement, valve removal and rarely surgical intervention (212).

Patients who develop complete atelectasis after valve placement show improvements in lung function, exercise capacity, QoL and survival(213)

Lung volume reduction coil treatment (LVRC)

LVRC (PneumRx/BTG, CA, USA) is a bronchoscopic treatment for emphysema patients with severe hyperinflation (Residual Volume (RV)>200% of predicted), absence of significant airway pathology,(214) who are not candidates for EBV or LVRS (215). The LVRC is a shape-memory nitinol implant (Figure 7) of which 10 to 14 are fluoroscopically placed in the most diseased lobe of each lung during sequential bronchoscopic procedures.(216) LVRC reduces static hyperinflation by improving airway resistance, and from secondary inflammation due to

mechanical tissue stress.(217-220) Initial trials showed improved pulmonary function, quality of life and exercise performance.(219, 221-224) A larger randomized controlled trial failed to reproduce earlier trial results, but still showed improved lung function and quality of life.(217) The benefits of LVRC treatment persist for up to three years,(224) and can potentially be repeated, however, the benefit is not as robust as initial treatment.(225) A U.S. Food and Drug Administration (FDA) panel concluded that LVRC benefits did not outweigh risks and it was denied clinical approval.(226) A sub analysis of RENEW suggests that patients with a RV > 200%, absence of airways disease and coil placement in the lobe with most emphysema had better outcomes.(214) These parameters are used for entry criteria in an ongoing trial.(227).

Thermal Vapor Ablation / Polymeric Lung Volume Reduction

Bronchoscopic Thermal Vapor Ablation (BTVA) and Polymeric Lung Volume Reduction (PLVR) target hyperinflation in symptomatic emphysema patients despite optimal pharmacological treatment. Both techniques incite inflammatory reactions to induce reduction of emphysematous areas. BTVA and PLVR treatments have some advantages over EBV, their efficacy does not depend on collateral ventilation and treatment occurs on a segmental not lobar level. Segmental treatment is important since many patients have intralobar heterogeneity.(228) The disadvantage of BTVA and PLVR is their irreversibility.

During BTVA, segmental application of 100°C heated water vapor promotes inflammation to induce volume reduction of emphysematous segments.(229) A RCT confirmed the efficacy of BTVA in 46 patients with upper lobe predominant emphysema.(230) At 6 months following bilateral treatment, significant improvements in FEV₁ and SGRQ occurred. BTVA is being evaluated for patients with homogeneous emphysema. (ClinicalTrials.gov Identifier: NCT03670121)

PLVR deploys a synthetic polymer into emphysematous lung segments to induce inflammation and resultant volume reduction. A RCT evaluated the safety and efficacy of PLVR in 34 patients with upper lobe predominant emphysema and showed significant improvement in lung function.(231) However, the procedure had a high rate of adverse events. The results of another multicenter RCT are pending. (ClinicalTrials.gov Identifier: NCT00884962)

Since both techniques induce inflammatory reactions, their most common adverse events are COPD exacerbations, and pneumonitis/pneumonia. BTVA has limited clinical availability and PLVR is currently under clinical trial investigation.

Targeted Lung Denervation

Reflex signaling via pulmonary branches of the vagus nerve is involved in the pathophysiology of COPD (232). Airway submucosal glands are innervated by pulmonary ganglion (233) and stimulation of parasympathetic efferent or sensory afferent (C fibers and stretch receptors) fibers initiate direct (efferent) (234) or reflex (afferent) (235, 236) mucus hypersecretion. Vagal nerve signaling facilitates disease-related airway hyperresponsiveness, and vagotomy abolishes the effect (237, 238). Cholinergic hyperactivity in COPD causes airways hyperresponsiveness, airflow limitation, gas trapping, mucus hypersecretion, and exacerbations. Blocking parasympathetic efferent lung signaling may complement bronchodilator therapies for COPD.

Targeted Lung Denervation (TLD) targets parasympathetic branches of the vagus nerve that run alongside the mainstem bronchi (Figure 8). TLD directs radiofrequency energy to pulmonary branches of the vagus nerve to disrupt signaling to and from the lung. TLD uses dual-cooled technology to protect the airway epithelial surface while delivering heat to a targeted depth where pulmonary vagus nerve branches reside. A preclinical study demonstrated that TLD disrupts vagal fibers histologically and produces physiologic changes associated with sensory/motor reflex signaling (239).

The first-in-man clinical study of TLD, IPS-I, demonstrated that TLD provides a bronchodilator effect similar to anticholinergic therapy with a dose (power) dependency effect (240). TLD with an inhaled anticholinergic produced greater bronchodilator effect than either therapy alone (241). IPS-II demonstrated the feasibility and safety of a single whole lung TLD procedure (242).

AIRFLOW 1 confirmed safety and feasibility with a flexible bronchoscope, reduced gastrointestinal side effects associated with ablation near the esophagus, and the safety of TLD using a 32W dose. (243) AIRFLOW 2 demonstrated that TLD treatment produced less airway related adverse events and fewer COPD hospitalizations (ClinicalTrials.gov Identifier: NCT02058459). An international multicenter randomized sham controlled TLD trial is evaluating if TLD reduces COPD exacerbations. (ClinicalTrials.gov Identifier: NCT03639051)

Chronic bronchitis

Chronic bronchitis patients have a poor quality of life, increased hospitalizations, greater lung function decline and increased mortality. It is characterized by excessive mucus hypersecretion by goblet cells predominantly located in the large airways. Treatments include smoking cessation, mucolytics, macrolides, anticholinergic agents, PDE-4 inhibitors, glucocorticoids, and chest physiotherapy; but are limited in treating symptoms or halting disease progression. (244, 245)

Bronchial Rheoplasty

Bronchial rheoplasty (RheOx System™ (Gala Therapeutics, Menlo Park, CA) delivers non-thermal energy to ablate airway mucosal cells and reduce goblet cell hyperplasia. The RheOx catheter is inserted via a bronchoscope from the subsegmental airways to the main carina while energy is delivered during electrode expansion (Figure 9).

In a multi-center feasibility study 25 patients with symptomatic chronic bronchitis underwent rheoplasty; procedure success was 100%. (13). Two patients experienced serious device-related adverse event (pleural effusion and mucosal scarring); four patients had 7 COPD hospitalizations. Most adverse events occurred within 30 days of bronchoscopy. Significant improvements in SGRQ and CAT scores were observed at 6- and 12-months. A reduction in goblet cell hyperplasia was observed. A U.S. clinical study is underway. (ClinicalTrials.gov Identifier: NCT03631472)

Liquid Nitrogen Metered Cryospray

The Rejuvenair Liquid Nitrogen Metered Cryospray™ (CSA Medical, MA, USA) is another potential bronchoscopic treatment for chronic bronchitis (Figure 10). It ablates diseased airway epithelial using liquid nitrogen at -196°C, thereby inducing a non-scarring, non-inflammatory healing process.(246) The system delivers pre-determined quantities of liquid nitrogen depending on anatomic site and gender and is locally controlled by thermocouple feedback. Treatment is performed in two sequential bronchoscopic procedures of approximately 45 minutes with intermittent airway circuit interruption to permit nitrogen gas egress. The Rejuvenair system was first tested in humans with sprays delivered into a resected lobe to demonstrate feasibility and safety.(247) It's use for treatment of chronic bronchitis is under investigation (Rejuvenair® study - ClinicalTrials.gov Identifier: NCT02483637).

Parenchymal lung diseases: Diagnosis

Diagnosis of diffuse parenchymal lung diseases (DPLD) relies on multidisciplinary evaluation.(248) Histologic data contributes to the diagnosis.(249-251) Surgical lung biopsies, the historical gold standard, are performed annually in $\geq 10,000$ U.S. patients and provides samples of size and quality generally sufficient for a diagnosis. However surgery has increased risks; in-hospital mortality is 1.7% and 16% for elective and non-elective procedures,

respectively.(252) Accordingly, less invasive alternatives are needed. Transbronchial forceps biopsies have a diagnostic yield of ~ 20% in DPLD.(253-255)

Transbronchial cryobiopsies have been proposed as a possible option. They are performed via either flexible or rigid bronchoscopy, using a cryoprobe advanced under fluoroscopy to the lung periphery, approximately 1 cm from the pleura. The probe is activated, releasing compressed gas (carbon dioxide or nitrous oxide) to the probe tip which instantly freezes lung tissue that is extracted, en-bloc with the bronchoscope.(256) Biopsies typically measure 5 mm, are devoid of crush artifact, and have superior histopathologic quality to forceps biopsies. There are, however, major downsides. Biopsy size precludes extraction through the working channel of the flexible bronchoscope: both must be removed together which exposes the patient to potentially severe endobronchial bleeding without maintaining a wedged position. Clinically significant bleeding occurs in 40% of patients. Cryobiopsies obtained at the lung periphery cause pneumothorax in 12%.(257) Mortality after cryobiopsy remains substantial, estimated around 0.3%.(139)

Cryobiopsy techniques vary considerably and the role of cryobiopsy remains controversial.(258) Besides procedural risks, critics highlight a lower diagnostic yield of cryobiopsies compared to surgical lung biopsies, estimated at 80% and 95%, respectively, and the lack of direct comparisons.(139) Proponents of the procedure offer counter arguments: 1) cryobiopsy and surgical lung biopsy offer comparable data to a multidisciplinary team (259), and 2) head-to-head comparisons only address histologic sample quality which needs to be balanced with the risks inherent to intervention. In that regard, cryobiopsies remain a promising alternative to the status quo. Detailed recommendations on effective and safe cryobiopsy practice provide guidance on patient selection, the need for multidisciplinary discussion, use of an endobronchial blocker to mitigate bleeding, and the need for proper training and expertise.(259)

Certification Training issues

The time-honored apprenticeship model of “see one, learn one, teach one” is not acceptable. Its flaws include training on real patients in high-stress environments, inadequate preparation for uncommon events, and the absence of systemic and structured feedback. (260)

For the cognitive component of procedural training, traditional tools such as books and lectures should be supplemented with newer approaches like interactive on-line learning and case-based discussion. Teaching should address all procedural aspects including patient selection, pre-procedural, procedural, and post procedural care and communication of results to patients and the care team. It's critical to educate proceduralists on when and how to decline a procedural request and the education of referring health care providers. (261)

Simulation is an effective tool for teaching bronchoscopy skills and available in two forms: low and high fidelity. (262, 263) Low fidelity simulation consists of molded models that offer realistic airway-like structure or silicone-based lymph nodes so learners can master anatomy and practice various sampling techniques. High fidelity simulation consists of computer-generated three-dimensional models of the airways, lymph nodes and vessels with various iterations of anatomy, clinical situations and even complications. High-fidelity simulation facilitates acquisition of bronchoscopy skills.(262, 264) Simulation models are available for basic bronchoscopy and EBUS skills. Explanted animals' lungs or cadavers are effective in training for higher-risk procedures (e.g., cryobiopsy, ablation therapy or stent placement).

Measuring competency in procedural performance is critical to assure best outcomes. Earlier guidelines published focused on procedural volume to determine competency.(110, 265) However, this approach is less favorable since learners acquire skills at different volume thresholds.

Newer guidelines emphasize the need to move to skill acquisition and knowledge-based assessments.(266) Checklist-based assessment tools aid assessment of the learner performing the procedure and scores procedural steps based on objective criteria. These tools are validated and reliable in discriminating skill levels.

Optimal training in interventional bronchoscopic procedures should incorporate traditional models (lecture, books) and newer approaches including digital media platforms, case-based interaction and simulation.

Interventional bronchoscopy: The future

In the near future, new approaches for many different lung diseases should become available: biodegradable stents, 2nd and 3rd generation endobronchial valves, better nonpharmacological treatments for chronic bronchitis and airflow obstruction, and new treatments in patients with emphysema who exhibit collateral ventilation (267). Ablative procedures for early cancerous lesions will advance and clinical trials will determine their effectiveness.

In order to access small peripheral lesions precisely, navigational methods need further development. The advantages and disadvantages of ultrathin bronchoscopy, thin bronchoscopy with guided sheath catheters and robotic assisted bronchoscopy requires comparative studies of diagnostic yields and cost effectiveness.(73, 75) Imaging support during the procedures must be improved. Smaller EBUS bronchoscopes and rEBUS tipped biopsy catheters should be compared to cone-beam-CT and augmented fluoroscopy in their abilities to provide real-time confirmation of lesion access during diagnostic and treatment interventions (268). This is especially true for semi-solid lesions where rEBUS currently has limitations.

The importance of training clinicians to be well versed in bronchial and lung anatomy who perform bronchoscopy is paramount and must be coupled with the skills need to navigate the

bronchoscope. Additionally, although significant advances have been made to improve the technology of bronchial navigation devices and real-time imaging modalities, less impressive advances have been made in developing new diagnostic tools.

To be able to improve our ability to diagnose and potential treat small peripheral malignant lung nodules, tools that can maneuver in the close and more angulated environment of the small airways must be developed. Several new needles have been developed to provide enhanced flexible in the smaller airways during greater degrees of articulation. The PeriView FLEX TBNA 21 -G (Olympus) and Arc point (Medtronic) 21 and 18 G- needles are examples. The GenCut core biopsy system (Medtronic) is another example of a more flexible tool that may help provide higher diagnostic yield in the smaller airways. However, the clinical usefulness of these tools needs validation. Overall, our ability to treat a lesion depends on our ability to reach it, and then fully access it. More tools that can allow us to achieve those goals are needed.

Navigational and biopsy tools must be studied in clinical settings to determine their effectiveness. The AQUiRE (ACCP Quality Improvement Registry, Evaluation, and Education) program evaluated diagnostic yields of different types of bronchoscopy in clinical practice to identify factors that affect diagnostic yield.(269) They found peripheral TBNA improved diagnostic yield but was underused and diagnostic yields of ENB and r-EBUS were lower than expected. Registry data can help prompt better bronchoscopic instruction and tools for community pulmonologists.

Another area with clear potential for development for minimally invasive procedures in the lung is Natural Orifice Transluminal Endoscopic Surgery (NOTES). NOTES describes a wide spectrum of procedures that uses natural luminal access such as transgastric or transvaginal routes, but could have applicability for other organs, like the lung via the bronchoscope. (270) Since Phillipe Mouret of France performed the first laparoscopic cholecystectomy in 1987 (271),

NOTES has been studied in the mediastinum; predominately porcine models. Concerns regarding complications of transtracheal or esophageal mediastinoscopy, such as infection and bleeding and healing of the esophageal incision have limited progress. However, this technique could have potential for the diagnosis and treatment of select pulmonary lesions. Further study is required as NOTES techniques evolve.

Summary

A foreign body removed by G. Killian in 1896 was the first bronchoscopy that was subsequently followed by Chevalier Jackson, I. Kubo and others who further advanced bronchoscopic techniques. In the 1960's, S. Ikeda introduced the flexible bronchoscope as a diagnostic tool and in the 1970's, laser and stents fostered the growth of interventional bronchoscopy. With new options, new uses for interventional bronchoscopy are emerging and it's plausible that interventional pulmonology has enormous potential to provide safe and effective diagnostic and therapeutic procedures at reduced costs for many patients with a variety of lung disorders.

References

1. Zöllner F. Gustav Killian, father of bronchoscopy. *Arch Otolaryngol* 1965; 82: 656-659.
2. Lerner AD, Feller-Kopman D. Is bronchoscopic treatment of lung cancer possible? *Expert Rev Respir Med* 2019; 13: 1-3.
3. Herth FJ, Ernst A, Becker HD. Endobronchial ultrasound-guided transbronchial lung biopsy in solitary pulmonary nodules and peripheral lesions. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2002; 20: 972-974.
4. Steinfert DP, Khor YH, Manser RL, Irving LB. Radial probe endobronchial ultrasound for the diagnosis of peripheral lung cancer: systematic review and meta-analysis. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2011; 37: 902-910.
5. Tanner NT, Yarmus L, Chen A, Wang Memoli J, Mehta HJ, Pastis NJ, Lee H, Jantz MA, Nietert PJ, Silvestri GA. Standard Bronchoscopy With Fluoroscopy vs Thin Bronchoscopy and Radial Endobronchial Ultrasound for Biopsy of Pulmonary Lesions: A Multicenter, Prospective, Randomized Trial. *Chest* 2018; 154: 1035-1043.
6. Eberhardt R, Anantham D, Ernst A, Feller-Kopman D, Herth F. Multimodality bronchoscopic diagnosis of peripheral lung lesions: a randomized controlled trial. *American journal of respiratory and critical care medicine* 2007; 176: 36-41.

7. Steinfort DP, Bonney A, See K, Irving LB. Sequential multimodality bronchoscopic investigation of peripheral pulmonary lesions. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2016; 47: 607-614.
8. Schuhmann M, Eberhardt R, Herth FJ. Endobronchial ultrasound for peripheral lesions: a review. *Endosc Ultrasound* 2013; 2: 3-6.
9. Schwarz Y, Mehta AC, Ernst A, Herth F, Engel A, Besser D, Becker HD. Electromagnetic navigation during flexible bronchoscopy. *Respiration; international review of thoracic diseases* 2003; 70: 516-522.
10. Gex G, Pralong JA, Combescure C, Seijo L, Rochat T, Soccal PM. Diagnostic yield and safety of electromagnetic navigation bronchoscopy for lung nodules: a systematic review and meta-analysis. *Respiration; international review of thoracic diseases* 2014; 87: 165-176.
11. Zhang W, Chen S, Dong X, Lei P. Meta-analysis of the diagnostic yield and safety of electromagnetic navigation bronchoscopy for lung nodules. *J Thorac Dis* 2015; 7: 799-809.
12. Seijo LM. Electromagnetic navigation bronchoscopy: clinical utility in the diagnosis of lung cancer. *Lung Cancer (Auckl)* 2016; 7: 111-118.
13. Folch EE, Pritchett MA, Nead MA, Bowling MR, Murgu SD, Krinsky WS, Murillo BA, LeMense GP, Minnich DJ, Bansal S, Ellis BQ, Mahajan AK, Gildea TR, Bechara RI, Szejman E, Flandes J, Rickman OB, Benzaquen S, Hogarth DK, Linden PA, Wahidi MM, Mattingley JS, Hood KL, Lin H, Wolvers JJ, Khandhar SJ, Investigators NS. Electromagnetic Navigation

- Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study. *J Thorac Oncol* 2019; 14: 445-458.
14. Yarmus LB, Arias S, Feller-Kopman D, Semaan R, Wang KP, Frimpong B, Oakjones Burgess K, Thompson R, Chen A, Ortiz R, Lee HJ. Electromagnetic navigation transthoracic needle aspiration for the diagnosis of pulmonary nodules: a safety and feasibility pilot study. *J Thorac Dis* 2016; 8: 186-194.
15. Eberhardt R, Kahn N, Gompelmann D, Schumann M, Heussel CP, Herth FJ. LungPoint--a new approach to peripheral lesions. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2010; 5: 1559-1563.
16. Pertzov B, Gershman E, Kassirer M, Heching M, Rosengarten D, Kramer M. Use of the LUNGVISION Navigational System to improve diagnostic yield of peripheral lung nodule biopsy. 2019.
17. Tachihara M, Tamura D, Kiri T, Tokunaga S, Hatakeyama Y, Shinke H, Nagano T, Nakata K, Hazeki N, Kamiryo H, Kobayashi K, Nishimura Y. Bronchoscopy Using Virtual Navigation and Endobronchial Ultrasonography with a Guide Sheath (EBUS-GS) with or without Fluoroscopy for Peripheral Pulmonary Lesions. *Kobe J. Med. Sci.*; 2017. p. 99-104.
18. Herth FJ, Eberhardt R, Sterman D, Silvestri GA, Hoffmann H, Shah PL. Bronchoscopic transparenchymal nodule access (BTPNA): first in human trial of a novel procedure for sampling solitary pulmonary nodules. *Thorax* 2015; 70: 326-332.

19. Harzheim D, Sterman D, Shah PL, Eberhardt R, Herth FJ. Bronchoscopic Transparenchymal Nodule Access: Feasibility and Safety in an Endoscopic Unit. *Respiration; international review of thoracic diseases* 2016; 91: 302-306.

20. Herth FJF LS, Sun J, Lam B, Nader D, Idris J. Diagnosing Solitary Pulmonary Nodule's (SPN's) where there is no airway leading to the nodule. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2018: OA 2167.

21. Sobieszczyk MJ, Yuan Z, Li W, Krinsky W. Biopsy of peripheral lung nodules utilizing cone beam computer tomography with and without trans bronchial access tool: a retrospective analysis. *J Thorac Dis* 2018; 10: 5953-5959.

22. Bowling MR, Brown C, Anciano CJ. Feasibility and Safety of the Transbronchial Access Tool for Peripheral Pulmonary Nodule and Mass. *Ann Thorac Surg* 2017; 104: 443-449.

23. Anciano C, Brown C, Bowling M. Going Off Road: The First Case Reports of the Use of the Transbronchial Access Tool With Electromagnetic Navigational Bronchoscopy. *J Bronchology Interv Pulmonol* 2017; 24: 253-256.

24. Shinagawa N, Yamazaki K, Onodera Y, Asahina H, Kikuchi E, Asano F, Miyasaka K, Nishimura M. Factors related to diagnostic sensitivity using an ultrathin bronchoscope under CT guidance. *Chest* 2007; 131: 549-553.

25. Shinagawa N, Yamazaki K, Onodera Y, Miyasaka K, Kikuchi E, Dosaka-Akita H, Nishimura M. CT-guided transbronchial biopsy using an ultrathin bronchoscope with virtual bronchoscopic navigation. *Chest* 2004; 125: 1138-1143.
26. Ost D, Shah R, Anasco E, Lusardi L, Doyle J, Austin C, Fein A. A randomized trial of CT fluoroscopic-guided bronchoscopy vs conventional bronchoscopy in patients with suspected lung cancer. *Chest* 2008; 134: 507-513.
27. Ng CSH, Chu CM, Lo CK, Lau RWH. Hybrid operating room Dyna-computed tomography combined image-guided electromagnetic navigation bronchoscopy dye marking and hookwire localization video-assisted thoracic surgery metastasectomy. *Interact Cardiovasc Thorac Surg* 2018; 26: 338-340.
28. Hohenforst-Schmidt W, Zarogoulidis P, Vogl T, Turner JF, Browning R, Linsmeier B, Huang H, Li Q, Darwiche K, Freitag L, Simoff M, Kioumis I, Zarogoulidis K, Brachmann J. Cone Beam Computertomography (CBCT) in Interventional Chest Medicine - High Feasibility for Endobronchial Realtime Navigation. *J Cancer* 2014; 5: 231-241.
29. Hohenforst-Schmidt W, Zarogoulidis P, Pitsiou G, Linsmeier B, Tsavlis D, Kioumis I, Papadaki E, Freitag L, Tsiouda T, Turner JF, Browning R, Simoff M, Sachpekidis N, Tsakiridis K, Zaric B, Yarmus L, Baka S, Stratakos G, Rittger H. Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature. *J Cancer* 2016; 7: 377-390.

30. Pritchett MA, Schampaert S, de Groot JAH, Schirmer CC, van der Bom I. Cone-Beam CT With Augmented Fluoroscopy Combined With Electromagnetic Navigation Bronchoscopy for Biopsy of Pulmonary Nodules. *J Bronchology Interv Pulmonol* 2018; 25: 274-282.
31. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA. Optical coherence tomography. *Science* 1991; 254: 1178-1181.
32. Hanna N, Saltzman D, Mukai D, Chen Z, Sasse S, Milliken J, Guo S, Jung W, Colt H, Brenner M. Two-dimensional and 3-dimensional optical coherence tomographic imaging of the airway, lung, and pleura. *J Thorac Cardiovasc Surg* 2005; 129: 615-622.
33. Lee AM, Kirby M, Ohtani K, Candido T, Shalansky R, MacAulay C, English J, Finley R, Lam S, Coxson HO, Lane P. Validation of airway wall measurements by optical coherence tomography in porcine airways. *PLoS One* 2014; 9: e100145.
34. McLaughlin RA, Yang X, Quirk BC, Lorensen D, Kirk RW, Noble PB, Sampson DD. Static and dynamic imaging of alveoli using optical coherence tomography needle probes. *J Appl Physiol (1985)* 2012; 113: 967-974.
35. Meissner S, Knels L, Krueger A, Koch T, Koch E. Simultaneous three-dimensional optical coherence tomography and intravital microscopy for imaging subpleural pulmonary alveoli in isolated rabbit lungs. *J Biomed Opt* 2009; 14: 054020.
36. Quirk BC, McLaughlin RA, Curatolo A, Kirk RW, Noble PB, Sampson DD. In situ imaging of lung alveoli with an optical coherence tomography needle probe. *J Biomed Opt* 2011; 16: 036009.

37. Lam S, Standish B, Baldwin C, McWilliams A, leRiche J, Gazdar A, Vitkin AI, Yang V, Ikeda N, MacAulay C. In vivo optical coherence tomography imaging of preinvasive bronchial lesions. *Clin Cancer Res* 2008; 14: 2006-2011.
38. Michel RG, Kinasewitz GT, Fung KM, Keddissi JI. Optical coherence tomography as an adjunct to flexible bronchoscopy in the diagnosis of lung cancer: a pilot study. *Chest* 2010; 138: 984-988.
39. Tsuboi M, Hayashi A, Ikeda N, Honda H, Kato Y, Ichinose S, Kato H. Optical coherence tomography in the diagnosis of bronchial lesions. *Lung Cancer* 2005; 49: 387-394.
40. Adams DC, Hariri LP, Miller AJ, Wang Y, Cho JL, Villiger M, Holz JA, Szabari MV, Hamilos DL, Scott Harris R, Griffith JW, Bouma BE, Luster AD, Medoff BD, Suter MJ. Birefringence microscopy platform for assessing airway smooth muscle structure and function in vivo. *Sci Transl Med* 2016; 8: 359ra131.
41. Coxson HO, Quiney B, Sin DD, Xing L, McWilliams AM, Mayo JR, Lam S. Airway wall thickness assessed using computed tomography and optical coherence tomography. *Am J Respir Crit Care Med* 2008; 177: 1201-1206.
42. Kirby M, Ohtani K, Lopez Lisbona RM, Lee AM, Zhang W, Lane P, Varfolomeva N, Hui L, Ionescu D, Coxson HO, MacAulay C, FitzGerald JM, Lam S. Bronchial thermoplasty in asthma: 2-year follow-up using optical coherence tomography. *Eur Respir J* 2015; 46: 859-862.

43. Ding M, Chen Y, Guan WJ, Zhong CH, Jiang M, Luo WZ, Chen XB, Tang CL, Tang Y, Jian QM, Wang W, Li SY, Zhong NS. Measuring Airway Remodeling in Patients With Different COPD Staging Using Endobronchial Optical Coherence Tomography. *Chest* 2016; 150: 1281-1290.
44. Hariri LP, Adams DC, Wain JC, Lanuti M, Muniappan A, Sharma A, Colby TV, Mino-Kenudson M, Mark EJ, Kradin RL, Goulart H, Tager AM, Suter MJ. Endobronchial Optical Coherence Tomography for Low-Risk Microscopic Assessment and Diagnosis of Idiopathic Pulmonary Fibrosis In Vivo. *Am J Respir Crit Care Med* 2018; 197: 949-952.
45. Domingo E, Grignola JC, Aguilar R, Montero MA, Arredondo C, Vázquez M, López-Messeguer M, Bravo C, Bouteldja N, Hidalgo C, Roman A. In vivo assessment of pulmonary arterial wall fibrosis by intravascular optical coherence tomography in pulmonary arterial hypertension: a new prognostic marker of adverse clinical follow-up. *Open Respir Med J* 2013; 7: 26-32.
46. Jiang X, Peng FH, Liu QQ, Zhao QH, He J, Jiang R, Wang L, Xu XQ, Li JH, Ebrahimi R, Jing ZC. Optical coherence tomography for hypertensive pulmonary vasculature. *Int J Cardiol* 2016; 222: 494-498.
47. Wijmans L, d'Hooghe JN, Bonta PI, Annema JT. Optical coherence tomography and confocal laser endomicroscopy in pulmonary diseases. *Curr Opin Pulm Med* 2017; 23: 275-283.
48. Hariri LP, Adams DC, Applegate MB, Miller AJ, Roop BW, Villiger M, Bouma BE, Suter MJ. Distinguishing tumor from associated fibrosis to increase diagnostic biopsy yield with

- polarization-sensitive optical coherence tomography. *Clinical Cancer Research* 2019; 25: 5242-5249.
49. Fuchs FS, Zirlik S, Hildner K, Schubert J, Vieth M, Neurath MF. Confocal laser endomicroscopy for diagnosing lung cancer in vivo. *Eur Respir J* 2013; 41: 1401-1408.
50. Hassan T, Piton N, Lachkar S, Salaün M, Thiberville L. A Novel Method for In Vivo Imaging of Solitary Lung Nodules Using Navigational Bronchoscopy and Confocal Laser Microendoscopy. *Lung* 2015; 193: 773-778.
51. Sorokina A, Danilevskaya O, Averyanov A, Zabozlaev F, Sazonov D, Yarmus L, Lee HJ. Comparative study of ex vivo probe-based confocal laser endomicroscopy and light microscopy in lung cancer diagnostics. *Respirology* 2014; 19: 907-913.
52. Danilevskaya O, Averyanov A, Lesnyak V, Chernyaev A, Sorokina A. Confocal laser endomicroscopy for diagnosis and monitoring of pulmonary alveolar proteinosis. *J Bronchology Interv Pulmonol* 2015; 22: 33-40.
53. Yserbyt J, Alamé T, Doods C, Ninane V. Pulmonary alveolar microlithiasis and probe-based confocal laser endomicroscopy. *J Bronchology Interv Pulmonol* 2013; 20: 159-163.
54. Yserbyt J, Doods C, Decramer M, Verleden GM. Acute lung allograft rejection: diagnostic role of probe-based confocal laser endomicroscopy of the respiratory tract. *J Heart Lung Transplant* 2014; 33: 492-498.

55. Benias PC, D'Souza LS, Papafragkakis H, Kim J, Harshan M, Theise ND, Carr-Locke DL.
Needle-based confocal endomicroscopy for evaluation of malignant lymph nodes - a feasibility study. *Endoscopy* 2016; 48: 923-928.
56. van Boerdonk RA, Smesseim I, Heideman DA, Coupé VM, Tio D, Grünberg K, Thunnissen E, Snijders PJ, Postmus PE, Smit EF, Daniels JM, Sutedja TG. Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions. *Am J Respir Crit Care Med* 2015; 192: 1483-1489.
57. Advani M, Purohit G, Vyas S, Kumari J. Comparison of Diagnostic Potential of Narrow Band Imaging Bronchoscopy Over White Light Bronchoscopy in Lung Cancer. *J Bronchology Interv Pulmonol* 2018; 25: 132-136.
58. Herth FJ, Eberhardt R, Anantham D, Gompelmann D, Zakaria MW, Ernst A. Narrow-band imaging bronchoscopy increases the specificity of bronchoscopic early lung cancer detection. *J Thorac Oncol* 2009; 4: 1060-1065.
59. Shibuya K, Nakajima T, Fujiwara T, Chiyo M, Hoshino H, Moriya Y, Suzuki M, Hiroshima K, Nakatani Y, Yoshino I. Narrow band imaging with high-resolution bronchovideoscopy: a new approach for visualizing angiogenesis in squamous cell carcinoma of the lung. *Lung Cancer* 2010; 69: 194-202.
60. Vincent BD, Fraig M, Silvestri GA. A pilot study of narrow-band imaging compared to white light bronchoscopy for evaluation of normal airways and premalignant and malignant airways disease. *Chest* 2007; 131: 1794-1799.

61. Zhang J, Wu J, Yang Y, Liao H, Xu Z, Hamblin LT, Jiang L, Depypere L, Ang KL, He J, Liang Z, Huang J, Li J, He Q, Liang W. White light, autofluorescence and narrow-band imaging bronchoscopy for diagnosing airway pre-cancerous and early cancer lesions: a systematic review and meta-analysis. *J Thorac Dis* 2016; 8: 3205-3216.

62. Tremblay A, Taghizadeh N, McWilliams AM, MacEachern P, Stather DR, Soghrati K, Puksa S, Goffin JR, Yasufuku K, Amjadi K, Nicholas G, Martel S, Laberge F, Johnston M, Shepherd FA, Ionescu DN, Urbanski S, Hwang D, Cutz JC, Sekhon HS, Couture C, Xu Z, Sutedja TG, Atkar-Khattra S, Tammemagi MC, Tsao MS, Lam SC, Group P-CELCS. Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study. *Chest* 2016; 150: 1015-1022.

63. Thakrar RM, Pennycuik A, Borg E, Janes SM. Preinvasive disease of the airway. *Cancer Treat Rev* 2017; 58: 77-90.

64. Wisnivesky JP, Yung RC, Mathur PN, Zulueta JJ. Diagnosis and treatment of bronchial intraepithelial neoplasia and early lung cancer of the central airways: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013; 143: e263S-e277S.

65. Callahan S, Tanner N, Chen A, Macro T, Silvestri G, Pastis N. Comparison of the Thin Convex Probe Endobronchial Ultrasound Bronchoscope to Standard EBUS and Flexible

- Bronchoscope: A Cadaveric Study. 2016 [cited 2020 January 2, 2020]. Available from: [https://journal.chestnet.org/article/S0012-3692\(16\)57284-5/pdf](https://journal.chestnet.org/article/S0012-3692(16)57284-5/pdf).
66. Patel P, Wada H, Hu HP, Hirohashi K, Kato T, Ujiie H, Ahn JY, Lee D, Geddie W, Yasufuku K. First Evaluation of the New Thin Convex Probe Endobronchial Ultrasound Scope: A Human Ex Vivo Lung Study. *Ann Thorac Surg* 2017; 103: 1158-1164.
67. Rooney CP, Wolf K, McLennan G. Ultrathin bronchoscopy as an adjunct to standard bronchoscopy in the diagnosis of peripheral lung lesions. A preliminary report. *Respiration* 2002; 69: 63-68.
68. Oki M, Saka H, Ando M, Asano F, Kurimoto N, Morita K, Kitagawa C, Kogure Y, Miyazawa T. Ultrathin Bronchoscopy with Multimodal Devices for Peripheral Pulmonary Lesions. A Randomized Trial. *Am J Respir Crit Care Med* 2015; 192: 468-476.
69. Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. *Chest* 2012; 142: 385-393.
70. Franzen D, Diacon AH, Freitag L, Schubert PT, Wright CA, Schuurmans MM. Ultrathin bronchoscopy for solitary pulmonary lesions in a region endemic for tuberculosis: a randomised pilot trial. *BMC Pulm Med* 2016; 16: 62.
71. Asano F, Shinagawa N, Ishida T, Shindoh J, Anzai M, Tsuzuku A, Oizumi S, Morita S. Virtual bronchoscopic navigation combined with ultrathin bronchoscopy. A randomized clinical trial. *Am J Respir Crit Care Med* 2013; 188: 327-333.

72. Murgu SD. Robotic assisted-bronchoscopy: technical tips and lessons learned from the initial experience with sampling peripheral lung lesions. *BMC Pulm Med* 2019; 19: 89.
73. Rojas-Solano JR, Ugalde-Gamboa L, Machuzak M. Robotic Bronchoscopy for Diagnosis of Suspected Lung Cancer: A Feasibility Study. *J Bronchology Interv Pulmonol* 2018; 25: 168-175.
74. Chen AC, Gillespie CT. Robotic Endoscopic Airway Challenge: REACH Assessment. *Ann Thorac Surg* 2018; 106: 293-297.
75. Fielding DB, F; Hwa Son, J; Todman, M; Chin, A; Tan, L; Steinke, K; Windsor, MN; Sung, AW. FIRST HUMAN USE OF A NEW ROBOTIC-ASSISTED FIBER OPTIC SENSING NAVIGATION SYSTEM FOR SMALL PERIPHERAL PULMONARY NODULES. *Respiration; international review of thoracic diseases* 2019: epub ahead.
76. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S, Committee EG. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2017; 28: iv1-iv21.
77. Ghanem S, El Bitar S, Hossri S, Weerasinghe C, Atallah JP. What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist. *Cancer Manag Res* 2017; 9: 267-278.

78. Kang KH, Okoye CC, Patel RB, Siva S, Biswas T, Ellis RJ, Yao M, Machtay M, Lo SS.
Complications from Stereotactic Body Radiotherapy for Lung Cancer. *Cancers (Basel)*
2015; 7: 981-1004.
79. Xie F, Zheng X, Xiao B, Han B, Herth FJF, Sun J. Navigation Bronchoscopy-Guided
Radiofrequency Ablation for Nonsurgical Peripheral Pulmonary Tumors. *Respiration;
international review of thoracic diseases* 2017; 94: 293-298.
80. Tanabe T, Koizumi T, Tsushima K, Ito M, Kanda S, Kobayashi T, Yasuo M, Yamazaki Y, Kubo K,
Honda T, Kondo R, Yoshida K. Comparative study of three different catheters for CT
imaging-bronchoscopy-guided radiofrequency ablation as a potential and novel
interventional therapy for lung cancer. *Chest* 2010; 137: 890-897.
81. Koizumi T, Tsushima K, Tanabe T, Agatsuma T, Yokoyama T, Ito M, Kanda S, Kobayashi T,
Yasuo M. Bronchoscopy-Guided Cooled Radiofrequency Ablation as a Novel Intervention
Therapy for Peripheral Lung Cancer. *Respiration; international review of thoracic
diseases* 2015; 90: 47-55.
82. Hawk K DW, Rooks K, et al. Characterization of a bronchoscopic thermal ablation catheter in
porcine lung. *American journal of respiratory and critical care medicine* 2016; 193:
A6019.
83. Yamauchi Y, Izumi Y, Hashimoto K, Yashiro H, Inoue M, Nakatsuka S, Goto T, Anraku M,
Ohtsuka T, Kohno M, Kawamura M, Nomori H. Percutaneous cryoablation for the

treatment of medically inoperable stage I non-small cell lung cancer. *PLoS One* 2012; 7: e33223.

84. Zheng X, Yang C, Zhang X, Yuan H, Xie F, Li Y, Xu B, Herth FJF, Sun J. The Cryoablation for Peripheral Pulmonary Lesions Using a Novel Flexible Bronchoscopic Cryoprobe in the ex vivo Pig Lung and Liver. *Respiration; international review of thoracic diseases* 2019: 1-6.
85. Henne E, Ferguson JS, Mest R, Herth FJ. Thermal Vapor Ablation for Lung Lesions in a Porcine Model. *Respiration; international review of thoracic diseases* 2015; 90: 146-154.
86. Harms W, Krempien R, Grehn C, Hensley F, Debus J, Becker HD. Electromagnetically navigated brachytherapy as a new treatment option for peripheral pulmonary tumors. *Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]* 2006; 182: 108-111.
87. Imamura F, Ueno K, Kusunoki Y, Uchida J, Yoshimura M, Koizumi M, Yamasaki H, Nishiyama K. High-dose-rate brachytherapy for small-sized peripherally located lung cancer. *Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]* 2006; 182: 703-707.
88. Chen KC, Lee JM. Photodynamic therapeutic ablation for peripheral pulmonary malignancy via electromagnetic navigation bronchoscopy localization in a hybrid operating room (OR): a pioneering study. *J Thorac Dis* 2018; 10: S725-S730.

89. Kinoshita T, Effat A, Gregor A, Inage T, Ishiwata T, Motooka Y, Ujiie H, Wilson BC, Zheng G, Weersink R, Asamura H, Yasufuku K. A Novel Laser Fiberscope for Simultaneous Imaging and Phototherapy of Peripheral Lung Cancer. *Chest* 2019; 156: 571-578.
90. Ernst A, Feller-Kopman D, Becker HD, Mehta AC. Central airway obstruction. *Am J Respir Crit Care Med* 2004; 169: 1278-1297.
91. Murgu SD, Egressy K, Laxmanan B, Doblare G, Ortiz-Comino R, Hogarth DK. Central Airway Obstruction: Benign Strictures, Tracheobronchomalacia, and Malignancy-related Obstruction. *Chest* 2016; 150: 426-441.
92. Brouns M, Jayaraju ST, Lacor C, De Mey J, Noppen M, Vincken W, Verbanck S. Tracheal stenosis: a flow dynamics study. *J Appl Physiol (1985)* 2007; 102: 1178-1184.
93. Geffin B, Grillo HC, Cooper JD, Pontoppidan H. Stenosis following tracheostomy for respiratory care. *JAMA* 1971; 216: 1984-1988.
94. Hollingsworth HM. Wheezing and stridor. *Clin Chest Med* 1987; 8: 231-240.
95. Hindle H, Aldik MG, Marchbank A, Daneshvar C. Central Airway Obstruction in Bronchogenic Cancer: BMJ Publishing Group Ltd; 2016.
96. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee AvB, and Participating Institutions, Institutions IAftSoLCSaPFCABaP. The IASLC Lung Cancer Staging Project: Proposals for

Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016; 11: 39-51.

97. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, Committee IAftSoLCIS, Institutions P. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol* 2007; 2: 706-714.
98. Macchiarini P. Primary tracheal tumours. *Lancet Oncol* 2006; 7: 83-91.
99. Licht PB, Friis S, Pettersson G. Tracheal cancer in Denmark: a nationwide study. *Eur J Cardiothorac Surg* 2001; 19: 339-345.
100. Grillo HC, Donahue DM, Mathisen DJ, Wain JC, Wright CD. Postintubation tracheal stenosis. Treatment and results. *J Thorac Cardiovasc Surg* 1995; 109: 486-492; discussion 492-483.
101. Grillo HC, Mark EJ, Mathisen DJ, Wain JC. Idiopathic laryngotracheal stenosis and its management. *Ann Thorac Surg* 1993; 56: 80-87.
102. Keshishyan S, DeLorenzo L, Hammoud K, Avagyan A, Assallum H, Harris K. Infections causing central airway obstruction: role of bronchoscopy in diagnosis and management. *J Thorac Dis* 2017; 9: 1707-1724.

103. Baroni RH, Feller-Kopman D, Nishino M, Hatabu H, Loring SH, Ernst A, Boiselle PM.
Tracheobronchomalacia: comparison between end-expiratory and dynamic expiratory
CT for evaluation of central airway collapse. *Radiology* 2005; 235: 635-641.
104. Boiselle PM, Reynolds KF, Ernst A. Multiplanar and three-dimensional imaging of the
central airways with multidetector CT. *AJR Am J Roentgenol* 2002; 179: 301-308.
105. Gilkeson RC, Ciancibello LM, Hejal RB, Montenegro HD, Lange P. Tracheobronchomalacia:
dynamic airway evaluation with multidetector CT. *AJR Am J Roentgenol* 2001; 176: 205-
210.
106. Quint LE, Whyte RI, Kazerooni EA, Martinez FJ, Cascade PN, Lynch JP, Orringer MB,
Brunsting LA, Deeb GM. Stenosis of the central airways: evaluation by using helical CT
with multiplanar reconstructions. *Radiology* 1995; 194: 871-877.
107. Mathisen DJ, Grillo HC. Endoscopic relief of malignant airway obstruction. *Ann Thorac Surg*
1989; 48: 469-473; discussion 473-465.
108. Rahman NA, Fruchter O, Shitrit D, Fox BD, Kramer MR. Flexible bronchoscopic
management of benign tracheal stenosis: long term follow-up of 115 patients. *J*
Cardiothorac Surg 2010; 5: 2.
109. Herth F, Becker HD, LoCicero J, Ernst A. Endobronchial ultrasound in therapeutic
bronchoscopy. *Eur Respir J* 2002; 20: 118-121.

110. Bolliger CT, Mathur PN, Beamis JF, Becker HD, Cavaliere S, Colt H, Diaz-Jimenez JP, Dumon JF, Edell E, Kovitz KL, Macha HN, Mehta AC, Marel M, Noppen M, Strausz J, Sutedja TG, Society ERSAT. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. *Eur Respir J* 2002; 19: 356-373.
111. Guibert N, Mazieres J, Lepage B, Plat G, Didier A, Hermant C. Prognostic factors associated with interventional bronchoscopy in lung cancer. *Ann Thorac Surg* 2014; 97: 253-259.
112. Ost DE, Ernst A, Grosu HB, Lei X, Diaz-Mendoza J, Slade M, Gildea TR, Machuzak M, Jimenez CA, Toth J, Kovitz KL, Ray C, Greenhill S, Casal RF, Almeida FA, Wahidi M, Eapen GA, Yarmus LB, Morice RC, Benzaquen S, Tremblay A, Simoff M, Registry AB. Complications Following Therapeutic Bronchoscopy for Malignant Central Airway Obstruction: Results of the AQUIRE Registry. *Chest* 2015; 148: 450-471.
113. Cavaliere S, Venuta F, Foccoli P, Toninelli C, La Face B. Endoscopic treatment of malignant airway obstructions in 2,008 patients. *Chest* 1996; 110: 1536-1542.
114. Ost DE, Ernst A, Grosu HB, Lei X, Diaz-Mendoza J, Slade M, Gildea TR, Machuzak MS, Jimenez CA, Toth J, Kovitz KL, Ray C, Greenhill S, Casal RF, Almeida FA, Wahidi MM, Eapen GA, Feller-Kopman D, Morice RC, Benzaquen S, Tremblay A, Simoff M, Registry AB. Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. *Chest* 2015; 147: 1282-1298.

115. Amjadi K, Voduc N, Cruysberghs Y, Lemmens R, Fergusson DA, Doucette S, Noppen M.
Impact of interventional bronchoscopy on quality of life in malignant airway obstruction.
Respiration 2008; 76: 421-428.
116. Stratakos G, Gerovasili V, Dimitropoulos C, Giozos I, Filippidis FT, Gennimata S, Zarogoulidis P, Zissimopoulos A, Pataka A, Koufos N, Zakynthinos S, Syrigos K, Koulouris N. Survival and Quality of Life Benefit after Endoscopic Management of Malignant Central Airway Obstruction. *J Cancer* 2016; 7: 794-802.
117. Mahmood K, Wahidi MM, Thomas S, Argento AC, Ninan NA, Smathers EC, Shofer SL.
Therapeutic bronchoscopy improves spirometry, quality of life, and survival in central airway obstruction. *Respiration* 2015; 89: 404-413.
118. Colt HG, Harrell JH. Therapeutic rigid bronchoscopy allows level of care changes in patients with acute respiratory failure from central airways obstruction. *Chest* 1997; 112: 202-206.
119. Jeon K, Kim H, Yu CM, Koh WJ, Suh GY, Chung MP, Kwon OJ. Rigid bronchoscopic intervention in patients with respiratory failure caused by malignant central airway obstruction. *J Thorac Oncol* 2006; 1: 319-323.
120. Chhajed PN, Baty F, Pless M, Somandin S, Tamm M, Brutsche MH. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction. *Chest* 2006; 130: 1803-1807.

121. Verma A, Goh SK, Tai DYH, Kor AC, Soo CI, Seow DGF, Sein ZNN, Samol J, Chopra A, Abisheganaden J. Outcome of advanced lung cancer with central airway obstruction. *ERJ Open Res* 2018; 4.
122. Brutinel WM, Cortese DA, McDougall JC, Gillio RG, Bergstralh EJ. A two-year experience with the neodymium-YAG laser in endobronchial obstruction. *Chest* 1987; 91: 159-165.
123. Cavaliere S, Foccoli P, Farina PL. Nd:YAG laser bronchoscopy. A five-year experience with 1,396 applications in 1,000 patients. *Chest* 1988; 94: 15-21.
124. Dumon JF, Shapshay S, Bourcereau J, Cavaliere S, Meric B, Garbi N, Beamis J. Principles for safety in application of neodymium-YAG laser in bronchology. *Chest* 1984; 86: 163-168.
125. Venuta F, Rendina EA, De Giacomo T, Mercadante E, Francioni F, Pugliese F, Moretti M, Coloni GF. Nd:YAG laser resection of lung cancer invading the airway as a bridge to surgery and palliative treatment. *Ann Thorac Surg* 2002; 74: 995-998.
126. Crosta C, Spaggiari L, De Stefano A, Fiori G, Ravizza D, Pastorino U. Endoscopic argon plasma coagulation for palliative treatment of malignant airway obstructions: early results in 47 cases. *Lung Cancer* 2001; 33: 75-80.
127. Sutedja G, van Kralingen K, Schramel FM, Postmus PE. Fibreoptic bronchoscopic electrosurgery under local anaesthesia for rapid palliation in patients with central airway malignancies: a preliminary report. *Thorax* 1994; 49: 1243-1246.

128. Diaz-Jiménez JP, Martínez-Ballarín JE, Llunell A, Farrero E, Rodríguez A, Castro MJ. Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction. *Eur Respir J* 1999; 14: 800-805.
129. Minnich DJ, Bryant AS, Dooley A, Cerfolio RJ. Photodynamic laser therapy for lesions in the airway. *Ann Thorac Surg* 2010; 89: 1744-1748; discussion 1748-1749.
130. Browning R, Turner JF, Parrish S. Spray cryotherapy (SCT): institutional evolution of techniques and clinical practice from early experience in the treatment of malignant airway disease. *J Thorac Dis* 2015; 7: S405-414.
131. DiBardino DM, Lanfranco AR, Haas AR. Bronchoscopic Cryotherapy. Clinical Applications of the Cryoprobe, Cryospray, and Cryoadhesion. *Ann Am Thorac Soc* 2016; 13: 1405-1415.
132. Casal RF, Iribarren J, Eapen G, Ost D, Morice R, Lan C, Cornwell L, Almeida FA, Grosu H, Jimenez CA. Safety and effectiveness of microdebrider bronchoscopy for the management of central airway obstruction. *Respirology* 2013; 18: 1011-1015.
133. Lunn W, Garland R, Ashiku S, Thurer RL, Feller-Kopman D, Ernst A. Microdebrider bronchoscopy: a new tool for the interventional bronchoscopist. *Ann Thorac Surg* 2005; 80: 1485-1488.
134. Ball JB, Delaney JC, Evans CC, Donnelly RJ, Hind CR. Endoscopic bougie and balloon dilatation of multiple bronchial stenoses: 10 year follow up. *Thorax* 1991; 46: 933-935.

135. Kim JH, Shin JH, Song HY, Ko GY, Gwon DI, Yoon HK, Sung KB. Cutting balloon treatment for resistant benign bronchial strictures: report of eleven patients. *J Vasc Interv Radiol* 2010; 21: 748-752.
136. Hautmann H, Gamarra F, Pfeifer KJ, Huber RM. Fiberoptic bronchoscopic balloon dilatation in malignant tracheobronchial disease: indications and results. *Chest* 2001; 120: 43-49.
137. Nouraei SA, Sandhu GS. Outcome of a multimodality approach to the management of idiopathic subglottic stenosis. *Laryngoscope* 2013; 123: 2474-2484.
138. Shitrit D, Kuchuk M, Zismanov V, Rahman NA, Amital A, Kramer MR. Bronchoscopic balloon dilatation of tracheobronchial stenosis: long-term follow-up. *Eur J Cardiothorac Surg* 2010; 38: 198-202.
139. Sethi J, Ali MS, Mohananey D, Nanchal R, Maldonado F, Musani A. Are Transbronchial Cryobiopsies Ready for Prime Time?: A Systematic Review and Meta-Analysis. *J Bronchology Interv Pulmonol* 2019; 26: 22-32.
140. Oh SK, Park KN, Lee SW. Long-term results of endoscopic dilatation for tracheal and subglottic stenosis. *Clin Exp Otorhinolaryngol* 2014; 7: 324-328.
141. Sheski FD, Mathur PN. Long-term results of fiberoptic bronchoscopic balloon dilation in the management of benign tracheobronchial stenosis. *Chest* 1998; 114: 796-800.

142. Greer M, Fuehner T, Warnecke G, Noack H, Heilmann T, Haverich A, Welte T, Gottlieb J. Paclitaxel-coated balloons in refractory nonanastomotic airway stenosis following lung transplantation. *Am J Transplant* 2014; 14: 2400-2405.
143. Khan F, Anker CJ, Garrison G, Kinsey CM. Endobronchial ultrasound-guided transbronchial needle injection for local control of recurrent non-small cell lung cancer. *Ann Am Thorac Soc* 2015; 12: 101-104.
144. Lu B, Sun L, Yan X, Ai Z, Xu J. Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer. *Med Oncol* 2015; 32: 345.
145. Mehta HJ, Begnaud A, Penley AM, Wynne J, Malhotra P, Fernandez-Bussy S, Cope JM, Shuster JJ, Jantz MA. Treatment of isolated mediastinal and hilar recurrence of lung cancer with bronchoscopic endobronchial ultrasound guided intratumoral injection of chemotherapy with cisplatin. *Lung Cancer* 2015; 90: 542-547.
146. Dumon JF. A dedicated tracheobronchial stent. *Chest* 1990; 97: 328-332.
147. Noppen M, Piérard D, Meysman M, Claes I, Vincken W. Bacterial colonization of central airways after stenting. *Am J Respir Crit Care Med* 1999; 160: 672-677.
148. Dalar L, Karasulu L, Abul Y, Özdemir C, Sökücü SN, Tarhan M, Altin S. Bronchoscopic Treatment in the Management of Benign Tracheal Stenosis: Choices for Simple and Complex Tracheal Stenosis. *Ann Thorac Surg* 2016; 101: 1310-1317.

149. Bolliger CT, Sutedja TG, Strausz J, Freitag L. Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents. *Eur Respir J* 2006; 27: 1258-1271.
150. Chung FT, Chen HC, Chou CL, Yu CT, Kuo CH, Kuo HP, Lin SM. An outcome analysis of self-expandable metallic stents in central airway obstruction: a cohort study. *J Cardiothorac Surg* 2011; 6: 46.
151. Wood DE, Liu YH, Vallières E, Karmy-Jones R, Mulligan MS. Airway stenting for malignant and benign tracheobronchial stenosis. *Ann Thorac Surg* 2003; 76: 167-172; discussion 173-164.
152. Burns KE, Orons PD, Dauber JH, Grgurich WF, Stitt LW, Raghu S, Iacono AT. Endobronchial metallic stent placement for airway complications after lung transplantation: longitudinal results. *Ann Thorac Surg* 2002; 74: 1934-1941.
153. Chhajed PN, Malouf MA, Tamm M, Glanville AR. Ultraflex stents for the management of airway complications in lung transplant recipients. *Respirology* 2003; 8: 59-64.
154. Mughal MM, Gildea TR, Murthy S, Pettersson G, DeCamp M, Mehta AC. Short-term deployment of self-expanding metallic stents facilitates healing of bronchial dehiscence. *Am J Respir Crit Care Med* 2005; 172: 768-771.
155. Majid A, Alape D, Kheir F, Folch E, Ochoa S, Folch A, Gangadharan SP. Short-Term Use of Uncovered Self-Expanding Metallic Airway Stents for Severe Expiratory Central Airway Collapse. *Respiration* 2016; 92: 389-396.

156. Majid A, Kheir F, Chung J, Alape D, Husta B, Oh S, Folch E. Covered Balloon-Expanding Stents in Airway Stenosis. *J Bronchology Interv Pulmonol* 2017; 24: 174-177.
157. Sethi S, Gildea TR, Almeida FA, Cicienia JC, Machuzak MS. Clinical Success Stenting Distal Bronchi for "Lobar Salvage" in Bronchial Stenosis. *J Bronchology Interv Pulmonol* 2018; 25: 9-16.
158. Dutau H, Musani AI, Laroumagne S, Darwiche K, Freitag L, Astoul P. Biodegradable Airway Stents - Bench to Bedside: A Comprehensive Review. *Respiration* 2015; 90: 512-521.
159. Antón-Pacheco JL, Luna C, García E, López M, Morante R, Tordable C, Palacios A, de Miguel M, Benavent I, Gómez A. Initial experience with a new biodegradable airway stent in children: Is this the stent we were waiting for? *Pediatr Pulmonol* 2016; 51: 607-612.
160. Fuehner T, Suhling H, Greer M, Wiesner O, Dierich M, Warnecke G, Haverich A, Welte T, Gottlieb J. Biodegradable stents after lung transplantation. *Transpl Int* 2013; 26: e58-60.
161. Lischke R, Pozniak J, Vondrys D, Elliott MJ. Novel biodegradable stents in the treatment of bronchial stenosis after lung transplantation. *Eur J Cardiothorac Surg* 2011; 40: 619-624.
162. Lochbihler H, Hoelzl J, Dietz HG. Tissue compatibility and biodegradation of new absorbable stents for tracheal stabilization: an experimental study. *J Pediatr Surg* 1997; 32: 717-720.
163. Vondrys D, Elliott MJ, McLaren CA, Noctor C, Roebuck DJ. First experience with biodegradable airway stents in children. *Ann Thorac Surg* 2011; 92: 1870-1874.

164. Cheng GZ, Folch E, Brik R, Gangadharan S, Mallur P, Wilson JH, Husta B, Majid A. Three-dimensional modeled T-tube design and insertion in a patient with tracheal dehiscence. *Chest* 2015; 148: e106-e108.
165. Gildea TR, Young BP, Machuzak MS. Application of 3D Printing for Patient-Specific Silicone Stents: 1-Year Follow-Up on 2 Patients. *Respiration* 2018; 96: 488-494.
166. Guibert N, Didier A, Moreno B, Mhanna L, Brouchet L, Plat G, Hermant C, Mazieres J. Treatment of Post-transplant Complex Airway Stenosis with a Three-Dimensional, Computer-assisted Customized Airway Stent. *Am J Respir Crit Care Med* 2017; 195: e31-e33.
167. Guibert N, Moreno B, Plat G, Didier A, Mazieres J, Hermant C. Stenting of Complex Malignant Central-Airway Obstruction Guided by a Three-Dimensional Printed Model Of The Airways. *Ann Thorac Surg* 2017; 103: e357-e359.
168. Kurenov SN, Ionita C, Sammons D, Demmy TL. Three-dimensional printing to facilitate anatomic study, device development, simulation, and planning in thoracic surgery. *J Thorac Cardiovasc Surg* 2015; 149: 973-979.e971.
169. Tam MD, Laycock SD, Jayne D, Babar J, Noble B. 3-D printouts of the tracheobronchial tree generated from CT images as an aid to management in a case of tracheobronchial chondromalacia caused by relapsing polychondritis. *J Radiol Case Rep* 2013; 7: 34-43.
170. Herth FJ, Becker HD, Ernst A. Ultrasound-guided transbronchial needle aspiration: an experience in 242 patients. *Chest* 2003; 123: 604-607.

171. Vilmann P, Clementsen PF, Colella S, Siemsen M, De Leyn P, Dumonceau JM, Herth FJ, Larghi A, Vazquez-Sequeiros E, Hassan C, Crombag L, Korevaar DA, Konge L, Annema JT. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). *Endoscopy* 2015; 47: c1.
172. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, Harris LJ, Detterbeck FC. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013; 143: e211S-e250S.
173. Eapen GA, Shah AM, Lei X, Jimenez CA, Morice RC, Yarmus L, Filner J, Ray C, Michaud G, Greenhill SR, Sarkiss M, Casal R, Rice D, Ost DE, American College of Chest Physicians Quality Improvement Registry Eu, and Evaluation (AQuIRE) Participants. Complications, consequences, and practice patterns of endobronchial ultrasound-guided transbronchial needle aspiration: Results of the AQuIRE registry. *Chest* 2013; 143: 1044-1053.
174. Wallace MB, Pascual JM, Raimondo M, Woodward TA, McComb BL, Crook JE, Johnson MM, Al-Haddad MA, Gross SA, Pungpapong S, Hardee JN, Odell JA. Minimally invasive endoscopic staging of suspected lung cancer. *JAMA* 2008; 299: 540-546.
175. Annema JT, van Meerbeeck JP, Rintoul RC, Dooms C, Deschepper E, Dekkers OM, De Leyn P, Braun J, Carroll NR, Praet M, de Ryck F, Vansteenkiste J, Vermassen F, Versteegh MI,

- Veselić M, Nicholson AG, Rabe KF, Tournoy KG. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. *JAMA* 2010; 304: 2245-2252.
176. Kuijvenhoven JC, Korevaar DA, Tournoy KG, Malfait TL, Dooms C, Rintoul RC, Annema JT. Five-Year Survival After Endosonography vs Mediastinoscopy for Mediastinal Nodal Staging of Lung Cancer. *JAMA* 2016; 316: 1110-1112.
177. Herth FJ, Eberhardt R, Krasnik M, Ernst A. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. *Chest* 2008; 133: 887-891.
178. Bugalho A, de Santis M, Slubowski A, Rozman A, Eberhardt R. Trans-esophageal endobronchial ultrasound-guided needle aspiration (EUS-B-NA): A road map for the chest physician. *Pulmonology* 2017.
179. Herth F, Ernst A, Schulz M, Becker H. Endobronchial ultrasound reliably differentiates between airway infiltration and compression by tumor. *Chest* 2003; 123: 458-462.
180. Saji J, Kurimoto N, Morita K, Nakamura M, Inoue T, Nakamura H, Miyazawa T. Comparison of 21-gauge and 22-gauge Needles for Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration of Mediastinal and Hilar Lymph Nodes. *J Bronchology Interv Pulmonol* 2011; 18: 239-246.

181. Kinoshita T, Ujiie H, Schwock J, Fujino K, McDonald C, Lee CY, Gregor A, Tyan CC, Houston S, Czarnecka-Kujwa K, Asamura H, Yasufuku K. Clinical evaluation of the utility of a flexible 19-gauge EBUS-TBNA needle. *J Thorac Dis* 2018; 10: 2388-2396.
182. Herth FJ, Morgan RK, Eberhardt R, Ernst A. Endobronchial ultrasound-guided miniforceps biopsy in the biopsy of subcarinal masses in patients with low likelihood of non-small cell lung cancer. *Ann Thorac Surg* 2008; 85: 1874-1878.
183. Lee HS, Lee GK, Kim MS, Lee JM, Kim HY, Nam BH, Zo JI, Hwangbo B. Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station? *Chest* 2008; 134: 368-374.
184. Sehgal IS, Dhooria S, Aggarwal AN, Agarwal R. Impact of Rapid On-Site Cytological Evaluation (ROSE) on the Diagnostic Yield of Transbronchial Needle Aspiration During Mediastinal Lymph Node Sampling: Systematic Review and Meta-Analysis. *Chest* 2018; 153: 929-938.
185. Labarca G, Folch E, Jantz M, Mehta HJ, Majid A, Fernandez-Bussy S. Adequacy of Samples Obtained by Endobronchial Ultrasound with Transbronchial Needle Aspiration for Molecular Analysis in Patients with Non-Small Cell Lung Cancer. Systematic Review and Meta-Analysis. *Ann Am Thorac Soc* 2018; 15: 1205-1216.

186. Stevenson T, Powari M, Bowles C. Evolution of a rapid onsite evaluation (ROSE) service for endobronchial ultrasound guided (EBUS) fine needle aspiration (FNA) cytology in a UK Hospital: A 7 year audit. *Diagn Cytopathol* 2018; 46: 656-662.
187. Fujiwara T, Yasufuku K, Nakajima T, Chiyo M, Yoshida S, Suzuki M, Shibuya K, Hiroshima K, Nakatani Y, Yoshino I. The utility of sonographic features during endobronchial ultrasound-guided transbronchial needle aspiration for lymph node staging in patients with lung cancer: a standard endobronchial ultrasound image classification system. *Chest* 2010; 138: 641-647.
188. Wang L, Wu W, Hu Y, Teng J, Zhong R, Han B, Sun J. Sonographic Features of Endobronchial Ultrasonography Predict Intrathoracic Lymph Node Metastasis in Lung Cancer Patients. *Ann Thorac Surg* 2015; 100: 1203-1209.
189. Fournier C, Dhalluin X, Wallyn F, Machuron F, Bouchindhomme B, Copin MC, Valentin V. Performance of Endobronchial Ultrasound Elastography in the Differentiation of Malignant and Benign Mediastinal Lymph Nodes: Results in Real-life Practice. *J Bronchology Interv Pulmonol* 2018.
190. Chernyavsky IL, Russell RJ, Saunders RM, Morris GE, Berair R, Singapuri A, Chachi L, Mansur AH, Howarth PH, Dennison P, Chaudhuri R, Bicknell S, Rose FRAJ, Siddiqui S, Brook BS, Brightling CE. *Eur Respir J* 2018; 51.
191. Brown RH, Wizeman W, Danek C, Mitzner W. Effect of bronchial thermoplasty on airway distensibility. *Eur Respir J* 2005; 26: 277-282.

192. Pretolani M, Dombret MC, Thabut G, Knap D, Hamidi F, Debray MP, Taille C, Chanez P, Aubier M. Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. *Am J Respir Crit Care Med* 2014; 190: 1452-1454.
193. Chakir J, Haj-Salem I, Gras D, Joubert P, Beaudoin È, Biardel S, Lampron N, Martel S, Chanez P, Boulet LP, Laviolette M. Effects of Bronchial Thermoplasty on Airway Smooth Muscle and Collagen Deposition in Asthma. *Ann Am Thorac Soc* 2015; 12: 1612-1618.
194. Pretolani M, Bergqvist A, Thabut G, Dombret MC, Knapp D, Hamidi F, Alavoine L, Taillé C, Chanez P, Erjefält JS, Aubier M. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations. *J Allergy Clin Immunol* 2017; 139: 1176-1185.
195. d'Hooghe JNS, Goorsenberg AWM, Ten Hacken NHT, Weersink EJM, Roelofs JJTH, Mauad T, Shah PL, Annema JT, Bonta PI, group Tr. Airway smooth muscle reduction after bronchial thermoplasty in severe asthma correlates with FEV. *Clin Exp Allergy* 2019; 49: 541-544.
196. Cox G, Miller JD, McWilliams A, Fitzgerald JM, Lam S. Bronchial thermoplasty for asthma. *Am J Respir Crit Care Med* 2006; 173: 965-969.
197. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, Olivenstein R, Pavord ID, McCormack D, Chaudhuri R, Miller JD, Laviolette M, Group ATS. Asthma control during the year after bronchial thermoplasty. *N Engl J Med* 2007; 356: 1327-1337.

198. Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, Chung KF, Laviolette M, Group RTS. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. *Am J Respir Crit Care Med* 2007; 176: 1185-1191.
199. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, Barbers R, Ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G, Group ATS. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. *Am J Respir Crit Care Med* 2010; 181: 116-124.
200. Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Hales JB, McEvoy C, Slebos DJ, Holmes M, Phillips MJ, Erzurum SC, Hanania NA, Sumino K, Kraft M, Cox G, Sterman DH, Hogarth K, Kline JN, Mansur AH, Louie BE, Leeds WM, Barbers RG, Austin JH, Shargill NS, Quiring J, Armstrong B, Castro M, Group AIRTS. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. *J Allergy Clin Immunol* 2013; 132: 1295-1302.
201. Chupp G, Laviolette M, Cohn L, McEvoy C, Bansal S, Shifren A, Khatri S, Grubb GM, McMullen E, Strauven R, Kline JN, Group OmotPS. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. *Eur Respir J* 2017; 50.

202. Macklem PT. Therapeutic implications of the pathophysiology of COPD. *Eur Respir J* 2010; 35: 676-680.
203. Valipour A, Herth FJ, Burghuber OC, Criner G, Vergnon JM, Goldin J, Sciurba F, Ernst A. Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy. *Eur Respir J* 2014; 43: 387-396.
204. Ninane V, Geltner C, Bezzi M, Foccoli P, Gottlieb J, Welte T, Seijo L, Zulueta JJ, Munavvar M, Rosell A, Lopez M, Jones PW, Coxson HO, Springmeyer SC, Gonzalez X. Multicentre European study for the treatment of advanced emphysema with bronchial valves. *Eur Respir J* 2012; 39: 1319-1325.
205. Wood DE, Nader DA, Springmeyer SC, Elstad MR, Coxson HO, Chan A, Rai NS, Mularski RA, Cooper CB, Wise RA, Jones PW, Mehta AC, Gonzalez X, Sterman DH. The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema. *J Bronchology Interv Pulmonol* 2014; 21: 288-297.
206. Eberhardt R, Gompelmann D, Schuhmann M, Heussel CP, Herth FJ. Complete unilateral vs partial bilateral endoscopic lung volume reduction in patients with bilateral lung emphysema. *Chest* 2012; 142: 900-908.
207. Herth FJF, Slebos DJ, Criner GJ, Shah PL. Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2017. *Respiration* 2017; 94: 380-388.

208. Herth FJ, Eberhardt R, Gompelmann D, Ficker JH, Wagner M, Ek L, Schmidt B, Slebos DJ. Radiological and clinical outcomes of using Chartis to plan endobronchial valve treatment. *Eur Respir J* 2013; 41: 302-308.
209. Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, Broman G, Hillerdal G, Mal H, Pison C, Briault A, Downer N, Darwiche K, Rao J, Hubner RH, Ruwwe-Glosenkamp C, Trosini-Desert V, Eberhardt R, Herth FJ, Derom E, Malfait T, Shah PL, Garner JL, Ten Hacken NH, Fallouh H, Leroy S, Marquette CH. A Multicenter RCT of Zephyr(R) Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). *Am J Respir Crit Care Med* 2017.
210. Klooster K, ten Hacken NH, Hartman JE, Kerstjens HA, van Rikxoort EM, Slebos DJ. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. *N Engl J Med* 2015; 373: 2325-2335.
211. Valipour A, Slebos DJ, Herth F, Darwiche K, Wagner M, Ficker JH, Petermann C, Hubner RH, Stanzel F, Eberhardt R. Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. *Am J Respir Crit Care Med* 2016; 194: 1073-1082.
212. Valipour A, Slebos DJ, de Oliveira HG, Eberhardt R, Freitag L, Criner GJ, Herth FJ. Expert statement: pneumothorax associated with endoscopic valve therapy for emphysema--potential mechanisms, treatment algorithm, and case examples. *Respiration* 2014; 87: 513-521.

213. Gompelmann D, Benjamin N, Bischoff E, Kontogianni K, Schuhmann M, Hoffmann H, Heussel CP, Herth FJF, Eberhardt R. Survival after Endoscopic Valve Therapy in Patients with Severe Emphysema. *Respiration* 2019; 97: 145-152.
214. Slebos DJ, Cicienia J, Sciurba FC, Criner GJ, Hartman JE, Garner J, Deslée G, Delage A, Jantz M, Marquette CH, Strange C, Hatipoglu U, Mehta AC, LaPrad AS, Schmid-Bindert G, Herth FJF, Shah PL, Group RS. Predictors of Response to Endobronchial Coil Therapy in Patients With Advanced Emphysema. *Chest* 2019; 155: 928-937.
215. Herth FJF, Slebos DJ, Criner GJ, Valipour A, Sciurba F, Shah PL. Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2019. *Respiration* 2019; 97: 548-557.
216. Slebos DJ, Ten Hacken NH, Hetzel M, Herth FJF, Shah PL. Endobronchial Coils for Endoscopic Lung Volume Reduction: Best Practice Recommendations from an Expert Panel. *Respiration* 2018; 96: 1-11.
217. Sciurba FC, Criner GJ, Strange C, Shah PL, Michaud G, Connolly TA, Deslée G, Tillis WP, Delage A, Marquette CH, Krishna G, Kalhan R, Ferguson JS, Jantz M, Maldonado F, McKenna R, Majid A, Rai N, Gay S, Dransfield MT, Angel L, Maxfield R, Herth FJ, Wahidi MM, Mehta A, Slebos DJ, Group RSR. Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. *JAMA* 2016; 315: 2178-2189.

218. van Geffen WH, Slebos DJ, Herth FJ, Kemp SV, Weder W, Shah PL. Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis. *Lancet Respir Med* 2019; 7: 313-324.
219. Klooster K, Ten Hacken NH, Franz I, Kerstjens HA, van Rikxoort EM, Slebos DJ. Lung volume reduction coil treatment in chronic obstructive pulmonary disease patients with homogeneous emphysema: a prospective feasibility trial. *Respiration* 2014; 88: 116-125.
220. Welling JBA, Slebos DJ. Lung volume reduction with endobronchial coils for patients with emphysema. *J Thorac Dis* 2018; 10: S2797-S2805.
221. Slebos DJ, Klooster K, Ernst A, Herth FJF, Kerstjens HAM. Bronchoscopic lung volume reduction coil treatment of patients with severe heterogeneous emphysema. *Chest* 2012; 142: 574-582.
222. Slebos DJ, Hartman JE, Klooster K, Blaas S, Deslee G, Gesierich W, Hetzel J, Hetzel M, McNulty W, Kemp SV, Kessler R, Leroy S, Stanzel F, Witt C, Zoumot Z, Herth FJ, Shah PL. Bronchoscopic Coil Treatment for Patients with Severe Emphysema: A Meta-Analysis. *Respiration* 2015; 90: 136-145.
223. Deslée G, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Thiberville L, Leroy S, Marceau A, Laroumagne S, Mallet JP, Dukic S, Barbe C, Bulsei J, Jolly D, Durand-Zaleski I, Marquette CH, Group RS. Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial. *JAMA* 2016; 315: 175-184.

224. Shah PL, Zoumot Z, Singh S, Bicknell SR, Ross ET, Quiring J, Hopkinson NS, Kemp SV, Group RtS. Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. *Lancet Respir Med* 2013; 1: 233-240.
225. Hartman JE, Klooster K, Gortzak K, ten Hacken NH, Slebos DJ. Long-term follow-up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysema. *Respirology* 2015; 20: 319-326.
226. FDA Executive Summary: Elevair Endobronchial Coil System. Available from: [fda.gov/media/113548/download](https://www.fda.gov/media/113548/download).
227. Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema (ELEVATE). 2019 [cited 2019 december 27]. Available from: <https://clinicaltrials.gov/ct2/show/NCT03360396?term=elevate&cond=Emphysema&draw=2&rank=1>.
228. Valipour A, Shah PL, Gesierich W, Eberhardt R, Snell G, Strange C, Barry R, Gupta A, Henne E, Bandyopadhyay S, Raffy P, Yin Y, Tschirren J, Herth FJ. Patterns of Emphysema Heterogeneity. *Respiration* 2015; 90: 402-411.
229. Gompelmann D, Shah PL, Valipour A, Herth FJF. Bronchoscopic Thermal Vapor Ablation: Best Practice Recommendations from an Expert Panel on Endoscopic Lung Volume Reduction. *Respiration* 2018; 95: 392-400.
230. Herth FJ, Valipour A, Shah PL, Eberhardt R, Grah C, Egan J, Ficker JH, Wagner M, Witt C, Liebers U, Hopkins P, Gesierich W, Phillips M, Stanzel F, McNulty WH, Petermann C,

- Snell G, Gompelmann D. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. *Lancet Respir Med* 2016; 4: 185-193.
231. Come CE, Kramer MR, Dransfield MT, Abu-Hijleh M, Berkowitz D, Bezzi M, Bhatt SP, Boyd MB, Cases E, Chen AC, Cooper CB, Flandes J, Gildea T, Gotfried M, Hogarth DK, Kolandaivelu K, Leeds W, Liesching T, Marchetti N, Marquette C, Mularski RA, Pinto-Plata VM, Pritchett MA, Rafeq S, Rubio ER, Slebos DJ, Stratakos G, Sy A, Tsai LW, Wahidi M, Walsh J, Wells JM, Whitten PE, Yusen R, Zulueta JJ, Criner GJ, Washko GR. A randomised trial of lung sealant versus medical therapy for advanced emphysema. *Eur Respir J* 2015; 46: 651-662.
232. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, Lopez Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2018 Report. *GOLD Report* 2018.
233. Cuthbert AW, Murthy M, Darlington AP. Neural control of submucosal gland and apical membrane secretions in airways. *Physiological reports* 2015; 3.
234. Ueki I, German VF, Nadel JA. Micropipette measurement of airway submucosal gland secretion. Autonomic effects. *The American review of respiratory disease* 1980; 121: 351-357.

235. Schultz HD, Roberts AM, Bratcher C, Coleridge HM, Coleridge JC, Davis B. Pulmonary C-fibers reflexly increase secretion by tracheal submucosal glands in dogs. *Journal of applied physiology* 1985; 58: 907-910.
236. Yu J, Schultz HD, Goodman J, Coleridge JC, Coleridge HM, Davis B. Pulmonary rapidly adapting receptors reflexly increase airway secretion in dogs. *Journal of applied physiology* 1989; 67: 682-687.
237. Buckner CK, Songsiridej V, Dick EC, Busse WW. In vivo and in vitro studies on the use of the guinea pig as a model for virus-provoked airway hyperreactivity. *The American review of respiratory disease* 1985; 132: 305-310.
238. McAlexander MA, Gavett SH, Kollarik M, Undem BJ. Vagotomy reverses established allergen-induced airway hyperreactivity to methacholine in the mouse. *Respiratory physiology & neurobiology* 2015; 212-214: 20-24.
239. Hummel JP, Mayse ML, Dimmer S, Johnson PJ. Physiologic and histopathologic effects of targeted lung denervation in an animal model. *Journal of applied physiology* 2019; 126: 67-76.
240. Slebos DJ, Klooster K, Koegelenberg CF, Theron J, Styen D, Valipour A, Mayse M, Bolliger CT. Targeted lung denervation for moderate to severe COPD: a pilot study. *Thorax* 2015; 70: 411-419.
241. Koegelenberg CF, Theron J, Slebos DJ, Klooster K, Mayse M, Gosens R. Antimuscarinic Bronchodilator Response Retained after Bronchoscopic Vagal Denervation in Chronic

- Obstructive Pulmonary Disease Patients. *Respiration; international review of thoracic diseases* 2016; 92: 58-60.
242. Valipour A, Asadi S, Pison C, Jondot M, Kessler R, Benneddif K, Deslee G, Verdier M, Slebos DJ, Mayse M. Long-term safety of bilateral targeted lung denervation in patients with COPD. *International journal of chronic obstructive pulmonary disease* 2018; 13: 2163-2172.
243. Valipour A, Shah PL, Pison C, Ninane V, Janssens W, Perez T, Kessler R, Deslee G, Garner J, Abele C, Hartman JE, Slebos DJ, On behalf of the AIRFLOW-1 Study Group. Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients. *Respiration* 2019: 1-11.
244. Mejza F, Gnatiuc L, Buist AS, Vollmer WM, Lamprecht B, Obaseki DO, Nastalek P, Nizankowska-Mogilnicka E, Burney PGJ, collaborators B, collaborators Bs. Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study. *Eur Respir J* 2017; 50.
245. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013; 187: 228-237.
246. Krinsky WS, Broussard JN, Sarkar SA, Harley DP. Bronchoscopic spray cryotherapy: assessment of safety and depth of airway injury. *J Thorac Cardiovasc Surg* 2010; 139: 781-782.

247. Slebos DJ, Breen D, Coad J, Klooster K, Hartman J, Browning R, Shah PL, McNulty WH, Mohsin MA, Irshad K. Safety and Histological Effect of Liquid Nitrogen Metered Spray Cryotherapy in the Lung. *Am J Respir Crit Care Med* 2017; 196: 1351-1352.
248. Flaherty KR, King TE, Jr., Raghu G, Lynch JP, 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? *Am J Respir Crit Care Med* 2004; 170: 904-910.
249. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med* 2018; 6: 138-153.
250. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson KC, American Thoracic Society ERSJRS, Latin American Thoracic S. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2018; 198: e44-e68.
251. Raghu G, Rochweg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D,

- Selman M, Theodore A, Wells AU, Hoogsteden H, Schunemann HJ, American Thoracic S, European Respiratory s, Japanese Respiratory S, Latin American Thoracic A. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med* 2015; 192: e3-19.
252. Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB. In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011. *Am J Respir Crit Care Med* 2016; 193: 1161-1167.
253. Berbescu EA, Katzenstein AL, Snow JL, Zisman DA. Transbronchial biopsy in usual interstitial pneumonia. *Chest* 2006; 129: 1126-1131.
254. Sheth JS, Belperio JA, Fishbein MC, Kazerooni EA, Lagstein A, Murray S, Myers JL, Simon RH, Sisson TH, Sundaram B, White ES, Xia M, Zisman D, Flaherty KR. Utility of Transbronchial vs Surgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease. *Chest* 2017; 151: 389-399.
255. Tomassetti S, Cavazza A, Colby TV, Ryu JH, Nanni O, Scarpi E, Tantalocco P, Buccioli M, Dubini A, Piciocchi S, Ravaglia C, Gurioli C, Casoni GL, Gurioli C, Romagnoli M, Poletti V. Transbronchial biopsy is useful in predicting UIP pattern. *Respir Res* 2012; 13: 96.
256. Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, Tomassetti S, Ryu JH, Fruchter O, Piciocchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagmeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB,

- Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V. Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. *Respiration* 2018; 95: 188-200.
257. Johansson KA, Marcoux VS, Ronksley PE, Ryerson CJ. Diagnostic Yield and Complications of Transbronchial Lung Cryobiopsy for Interstitial Lung Disease. A Systematic Review and Metaanalysis. *Ann Am Thorac Soc* 2016; 13: 1828-1838.
258. Patel NM, Borczuk AC, Lederer DJ. Cryobiopsy in the Diagnosis of Interstitial Lung Disease. A Step Forward or Back? *Am J Respir Crit Care Med* 2016; 193: 707-709.
259. Tomassetti S, Wells AU, Costabel U, Cavazza A, Colby TV, Rossi G, Sverzellati N, Carloni A, Carretta E, Buccioli M, Tantalocco P, Ravaglia C, Gurioli C, Dubini A, Piciocchi S, Ryu JH, Poletti V. Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2016; 193: 745-752.
260. Rodriguez-Paz JM, Kennedy M, Salas E, Wu AW, Sexton JB, Hunt EA, Pronovost PJ. Beyond "see one, do one, teach one": toward a different training paradigm. *Postgrad Med J* 2009; 85: 244-249.
261. Deshwal H, Avasarala SK, Ghosh S, Mehta AC. Forbearance With Bronchoscopy: A Review of Gratuitous Indications. *Chest* 2019; 155: 834-847.

262. Kennedy CC, Maldonado F, Cook DA. Simulation-based bronchoscopy training: systematic review and meta-analysis. *Chest* 2013; 144: 183-192.
263. McSparron JI, Michaud GC, Gordan PL, Channick CL, Wahidi MM, Yarmus LB, Feller-Kopman DJ, Makani SS, Koenig SJ, Mayo PH, Kovitz KL, Thomson CC, Committee S-bWGotATSE. Simulation for Skills-based Education in Pulmonary and Critical Care Medicine. *Ann Am Thorac Soc* 2015; 12: 579-586.
264. Wahidi MM, Silvestri GA, Coakley RD, Ferguson JS, Shepherd RW, Moses L, Conforti J, Que LG, Anstrom KJ, McGuire F, Colt H, Downie GH. A prospective multicenter study of competency metrics and educational interventions in the learning of bronchoscopy among new pulmonary fellows. *Chest* 2010; 137: 1040-1049.
265. Ernst A, Silvestri GA, Johnstone D, Physicians ACoC. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. *Chest* 2003; 123: 1693-1717.
266. Ernst A, Wahidi MM, Read CA, Buckley JD, Addrizzo-Harris DJ, Shah PL, Herth FJF, de Hoyos Parra A, Ornelas J, Yarmus L, Silvestri GA. Adult Bronchoscopy Training: Current State and Suggestions for the Future: CHEST Expert Panel Report. *Chest* 2015; 148: 321-332.
267. Hu Y, Cheng Y, Zhang H, Li A, Li S, Wang G. A New-Designed Lung-Bending Device for Bronchoscopic Lung Volume Reduction of Severe Emphysema: A Feasibility Study in Pigs. *Respiration; international review of thoracic diseases* 2019: 1-7.

268. Casal RF, Sarkiss M, Jones AK, Stewart J, Tam A, Grosu HB, Ost DE, Jimenez CA, Eapen GA.
Cone beam computed tomography-guided thin/ultrathin bronchoscopy for diagnosis of
peripheral lung nodules: a prospective pilot study. *J Thorac Dis* 2018; 10: 6950-6959.
269. Ost DE, Ernst A, Lei X, Kovitz KL, Benzaquen S, Diaz-Mendoza J, Greenhill S, Toth J, Feller-
Kopman D, Puchalski J, Baram D, Karunakara R, Jimenez CA, Filner JJ, Morice RC, Eapen
GA, Michaud GC, Estrada-Y-Martin RM, Rafeq S, Grosu HB, Ray C, Gilbert CR, Yarmus LB,
Simoff M, Registry AB. Diagnostic Yield and Complications of Bronchoscopy for
Peripheral Lung Lesions. Results of the AQUIRE Registry. *Am J Respir Crit Care Med* 2016;
193: 68-77.
270. Yip HC, Chiu PW. Recent advances in natural orifice transluminal endoscopic surgery†. *Eur
J Cardiothorac Surg* 2016; 49 Suppl 1: i25-30.
271. Mouret P. How I developed laparoscopic cholecystectomy. *Ann Acad Med Singapore* 1996;
25: 744-747.

Navigational Techniques		Imaging Assessment of Lung lesions		Accessing Lung lesions		Inspection of Lymph Nodes		Assessment of Mucosal lesions	
Technique	Pro/Con	Technique	Pro/Con	Technique	Pro/Con	Technique	Pro/Con	Technique	Pro/Con
EMB)	Navigation aid	HRCT	Enhanced imaging	Transbronchial Needle Aspirate	Readily available/cost effective	EBUS	Readily available/cost effective	OCT	In vivo cellular morphology
	Increased costs, special equipment and training		increased cost and radiation exposure		Insufficient DX tissue and complications of PTX and bleeding		Equipment and disposable costs and training		Investigational, unclear benefit
VBN	Navigation aid	Radial EBUS	Noninvasive Endobronchial Imaging	Transbronchial Lung biopsy	Readily available/cost effective	EBUS with mini forceps	Greater tissue volume	CLE	In vivo cellular morphology
	Increased costs, special equipment and training		Special training and equipment required		Insufficient DX tissue and complications of PTX and bleeding		Insufficient clinical data, disposable cots and training		Investigational, unclear benefit
Thin bronchoscopy with guide sheath	Peripheral access	Fused flouroscopy	Real-time visualization	Cryobiopsy	Greater tissue volume avoids crush artifact	Elastography	Noninvasive assessment of LN stiffness	Image enhancement	In vivo cellular morphology
	Insufficient DX tissue, special disposables and diagnostic tools		Special equipment, increased cost and radiation exposure		Insufficient DX tissue and complications of PTX and bleeding		Insufficient clinical data, increased equipment costs		Investigational, unclear benefit
Ultrathin bronchoscopy	Peripheral access	CT Bronchoscopy	Real time visualization	TPNA	Access extraluminal lesions	CT Bronchoscopy	Enhanced imaging	Radial EBUS	Noninvasive Endobronchial Imaging
	Insufficient DX tissue, special disposables and diagnostic tools		Limited access, increased cost and radiation exposure		Insufficient DX tissue and complications of PTX and bleeding		Limited access, increased cost and radiation exposure		Needs clinical data
Robotic bronchoscopy	Peripheral access/stability	CBCT + Augmented flouroscopy	Real-time visualization	Thin-EBUS	Noninvasive lung imaging	Thin-EBUS	Interlobar LN Real-time imaging	Thin-EBUS	Noninvasive Endobronchial Imaging
	Increased equipment costs, special disposables and diagnostic tools		Limited access, increased cost and radiation exposure		Investigational, unclear benefit		Investigational, unclear benefit		Investigational, unclear benefit

Table 1. Overview of Bronchoscopic Diagnostic Tools with Advantages and Disadvantages

Definition of abbreviations: HRCT, high resolution chest CT; EBUS, endobronchial ultrasound; PTX, pneumothorax; OCT, Optical coherence tomography; CLE, Confocal laser endomicroscopy; CBCT, cone beam CT; DX, diagnostic; EMB; electromagnetic bronchoscopy, VBN, Virtual bronchoscopic navigation; TPNA, transparenchymal nodule access

Table 2. Overview of Advantages and Disadvantages of Current and Potential Flexible Bronchoscopy Therapeutic Tools

Malignant Solitary Nodules and Lesions		Emphysema		Asthma		COPD				Large Airway abnormalities	
						Chronic Bronchitis		Exacerbation		Expiratory Airway collapse	
Radiofrequency Ablation	Treat cancerous SPN	Endo-bronchial valves	Lung volume reduction	Bronchial Thermo-plasty	Improve symptoms, reduce exacerbation	Rheoplasty ²	Improve symptoms, reduce exacerbation	Total Lung Denervation	Improve symptoms, reduce exacerbations	Tracheo-Broncho-malacia	Tracheal Patency
	Under investigation		PTX, exacerbation		Multiple procedures, exacerbation / PNA,		Under investigation		Under investigation		Granulation tissue and increased secretions
Microwave Ablation	Treat cancerous SPN	Thermal Vapor ablation	Lung volume reduction	Total Lung Denerva-tion	Improve symptoms, reduce exacerbation	Liquid Nitrogen Metered Cryospray	Improve symptoms, reduce exacerbation			Airway Stenting	Tracheal patency
	Under investigation		Exacerbation		Under investigation		Under investigation				Granulation tissue and increased secretions
Thermal Vapor Ablation	Treat cancerous SPN	Lung Coils	Lung volume reduction			Micro-debrider	Improve symptoms, reduce exacerbation				
	Under investigation		Under investigation, Exacerbation, PNA				Under investigation				
Cryoablation	Treat cancerous SPN	Polymeric agents	Lung volume reduction								
	Under investigation		Under investigation, Exacerbation, PNA								
Debridement (Laser, Electrocautery, Argon Plasma Coagulation, Microdebrider)	Treat cancerous lesions									Bronchial and Segmental Airway Stenosis	
	Special hardware, disposables and training, bleeding,										

	perforation, airway fire										
Brachytherapy	Treat cancerous SPN									Bronchoplasty	Airway Patency
	Need for trans laryngeal catheter										Need for repeat procedures
Chemo injection	Treat cancerous SPN									Airway Stenting	Airway patency
	Under investigation										Granulation tissue and increased secretions
Photodynamic Therapy	Treat cancerous lesions									Electrocautery	Airway patency
	Under investigation										Need for repeat procedures, cartilaginous injury
Airway Stenting	Airway patency										
	Granulation tissue and increased secretions										

Definition of abbreviations: PNA, pneumonia; PTX, pneumothorax

Figure 1. A radial EBUS probe in the center of a SPN.

Figure 2. Overlaid track from the VBN navigational pathway (right side) onto the bronchoscopic image (left side)

Figure 3, Panel A. View of Transparenchymal Nodule Access (TPNA) on an SPN in the RLL. Fused fluoroscopy is being used to create a fluoroscopically guided transparenchymal path to the superimposed target previously identified by planning HRCT. Purple dot represents virtual pleura. Multiple C-arm projections are used to confirm target location.

Panel B. Three-dimensional (3D) map shows the danger zones and exit point, and the target lesion are demonstrated. (Bowling AnnTS 2017;104: 443-339.)

Figure 4. A. Type 1 elastography pattern (homogenous green) in patient with tuberculosis. B. Type 2 elastography pattern (mixed color pattern) in patient with sarcoidosis C. Type 3 elastography pattern (homogenous blue) in patient with adenocarcinoma.

Figure 5. Overview of Survival and interventional therapies for advanced emphysema. (Modified from Vogelmeier AJRCCM, 2017)

Figure 6. Patient with advanced upper lobe emphysema before (A) and after endobronchial valve placement (B) in LUL showing total lobar occlusion and complete atelectasis. Valves are seen in panel C. Other EBV option (SVS, Spiration, Inc, Seattle WA.) shown in panel D.

A.

B.

C.

D.

Figure 7. Panel A. Nitinol lung volume reduction coil. Panel B. Coil deployed in lung.

Figure 8. Total Lung Denervation. Electrode positioned into the distal mainstem bronchi to deliver ablation treatment with thermal insulation provided to airway wall by water cooled jacket.

Figure 9. Rheoplasty. Expanded basket provides airway contact to deliver pulsed field energy to ablate airway epithelial goblet cells.

Figure 10. The Rejuvenair Liquid Nitrogen Metered Cryospray. Left panel: Bronchus intermedius with Rejuvenair catheter in situ just before treatment. Right panel: Liquid Nitrogen Metered Cryospray in action at the same position showing the desired circular freezing pattern.